{"ticker": {"uuid": "9c44c245-65f3-492b-bf15-2ea6b899e404", "symbol": "BHVN", "name": "Biohaven Ltd.", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "charts": {"tiers": [{"count": 46, "label": "Direct company coverage"}, {"count": 0, "label": "Industry context"}, {"count": 0, "label": "Sector context"}], "events": [{"count": 25, "label": "Earnings"}, {"count": 9, "label": "Market update"}, {"count": 8, "label": "Deals and strategy"}, {"count": 3, "label": "Analyst action"}, {"count": 1, "label": "Balance sheet"}], "sources": [{"label": "MarketBeat", "count": 9}, {"label": "vinanet.vn", "count": 5}, {"label": "Investing.com", "count": 3}, {"label": "finance.yahoo.com", "count": 2}, {"label": "PR Newswire", "count": 2}, {"label": "Simply Wall Street", "count": 2}, {"label": "Stock Titan", "count": 2}, {"label": "Motley Fool", "count": 1}]}, "insights": [{"text": "Balanced news tone", "tone": "neutral", "label": "Weighted tone", "value": "53/100"}, {"text": "9.25 effective stories after overlap and weighting.", "tone": "neutral", "label": "Evidence confidence", "value": "38/100"}, {"text": "Price is moving more forcefully than the current news tone suggests.", "tone": "positive", "label": "Market reaction", "value": "Price moving ahead of tone"}, {"text": "78/100 evidence concentration around this catalyst.", "tone": "neutral", "label": "Primary event", "value": "Earnings"}, {"text": "92% of weighted evidence is company-specific.", "tone": "positive", "label": "Company focus", "value": "46"}, {"text": "lower dispersion means the independent stories agree more closely.", "tone": "neutral", "label": "Evidence agreement", "value": "21/100"}, {"text": "+11.3% over one week, +14.1% over four weeks, trend active, and below fair value.", "tone": "positive", "label": "Trend context", "value": "Trend active"}, {"text": "Why Biohaven Stock Was Rocking the Market This Week", "tone": "neutral", "label": "Latest direct headline", "value": "Neutral"}], "classifier": {"events": [{"count": 25, "event": "earnings", "label": "Earnings", "weight": 15.2}, {"count": 9, "event": "general", "label": "Market update", "weight": 5.62}, {"count": 8, "event": "deals", "label": "Deals and strategy", "weight": 5.2}, {"count": 3, "event": "analyst", "label": "Analyst action", "weight": 2.02}, {"count": 1, "event": "liquidity", "label": "Balance sheet", "weight": 0.82}], "pipeline": {"status": "healthy", "providers_attempted": 3, "providers_with_results": 3, "raw_articles": 110, "unique_stories": 72, "duplicates_removed": 38, "relevant_stories": 46, "matched_archive_stories": 52, "current_evidence": 22, "direct_evidence": 46, "archive_articles": 30, "durable_story_count": 47, "durable_evidence_used": true, "durable_collected_at": "2026-08-28T15:58:11.364718+00:00"}, "confidence": 78, "primary_event": "earnings", "primary_label": "Earnings", "negative_events": 7, "positive_events": 15}, "updated_at": "2026-08-29T14:14:22.662668+00:00", "total_unique": 47, "total_fetched": 47, "interpretation": {"tone": "positive", "label": "Price moving ahead of tone", "risks": [], "badges": ["Value support"], "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 47, "event_label": "Earnings", "opportunities": ["Price is below fair value while news tone is not negative."], "classification": "price_leads_news", "sentiment_word": "balanced"}, "market_context": {"trend_tone": "positive", "latest_week": "2026-08-28", "trend_label": "Trend active", "latest_close": 15.41, "trend_signal": "1", "one_week_move": 11.3, "reaction_tone": "positive", "fair_value_gap": -42.9, "four_week_move": 14.1, "reaction_label": "Price confirming higher", "fair_value_tone": "positive", "market_dynamics": 0.815149, "market_sentence": "+11.3% over one week, +14.1% over four weeks, trend active, and below fair value.", "fair_value_label": "Below fair value", "twelve_week_move": 42.7, "relative_strength": 14.150829, "has_market_context": true, "expectation_direction": "undecided", "expectation_probability": 46.7119, "market_dynamics_buy_signal": false}, "total_relevant": 46, "pipeline_health": {"status": "healthy", "providers_attempted": 3, "providers_with_results": 3, "raw_articles": 110, "unique_stories": 72, "duplicates_removed": 38, "relevant_stories": 46, "matched_archive_stories": 52, "current_evidence": 22, "direct_evidence": 46, "archive_articles": 30, "durable_story_count": 46, "durable_evidence_used": true, "durable_collected_at": "2026-08-29T14:14:22.662668+00:00"}, "sentiment_summary": {"tone": "neutral", "label": "Balanced news tone", "score": 53, "total": 47, "neutral": 24, "negative": 7, "positive": 15, "raw_score": 56, "confidence": 38, "dispersion": 21, "story_count": 46, "window_days": 30, "direct_share": 92, "source_count": 13, "score_version": "evidence-v10", "evidence_count": 22, "evidence_status": "measured", "information_mass": 0.964, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-08-28T07:32:33+00:00", "direct_story_count": 46, "effective_articles": 9.25, "sector_story_count": 0, "direct_source_count": 13, "industry_story_count": 0, "source_concentration": 0.1286, "directional_story_count": 22}, "articles": [{"url": "https://finance.yahoo.com/m/16f3e772-1119-38de-adfd-c773a9f3693b/why-biohaven-stock-was.html", "tier": "direct", "title": "Why Biohaven Stock Was Rocking the Market This Week", "topics": [], "summary": "", "age_days": 1.3, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/m/16f3e772-1119-38de-adfd-c773a9f3693b/why-biohaven-stock-was.html", "source_name": "Motley Fool", "published_at": "2026-08-28T07:32:33+00:00", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 64.2, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.026318, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "28 Aug 2026 07:32", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/m/dd6dbde2-0638-3f03-a583-89d9e229d6ad/sk-inks-%24795m-biohaven.html", "tier": "direct", "title": "SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race", "topics": [], "summary": "", "age_days": 2.0, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/m/dd6dbde2-0638-3f03-a583-89d9e229d6ad/sk-inks-%24795m-biohaven.html", "source_name": "Pharmaceutical Technology", "published_at": "2026-08-27T14:40:43+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 82.2, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.060852, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "27 Aug 2026 14:40", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/healthcare/articles/bhvn-stock-soars-18-795m-134200709.html", "tier": "direct", "title": "BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program", "topics": ["Balance Sheet", "Biotech", "Earnings Per Share", "Epilepsy", "M A", "Partnership"], "summary": "Biohaven BHVN stock climbed 17.9% on Wednesday after the announcement of a strategic global licensing and collaboration agreement with South Korea-based SK Biopharmaceuticals. Under the deal, SK Biopharmaceuticals will receive exclusive worldwide rights to Biohaven's Kv7 ion channel platform, led by opakalim (BHV-7000), undergoing mid- to late-stage development for focal epilepsy. Under the terms, SK Biopharmaceuticals will provide upfront and milestone payments of up to $795 million related to the Kv7 platform. Biohaven will receive $400 million in cash consideration, including $350 million p", "age_days": 2.0, "is_stale": false, "sentiment": "positive", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/bhvn-stock-soars-18-795m-134200709.html", "source_name": "Zacks", "published_at": "2026-08-27T13:42:00+00:00", "tone_signals": ["Large positive market reaction", "Positive market reaction"], "company_focus": 0.78, "freshness_pct": 81.9, "sentiment_pct": 80, "evidence_basis": "archived_article", "evidence_share": 21.2, "score_included": true, "duplicate_count": 3, "evidence_weight": 0.204543, "influence_label": "High", "event_confidence": 61, "company_focus_pct": 78, "evidence_strength": 72, "published_display": "27 Aug 2026 13:42", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "21.2"}, {"url": "https://finance.yahoo.com/markets/stocks/articles/biohaven-shares-rise-epilepsy-drug-182910055.html", "tier": "direct", "title": "Update: Biohaven Shares Rise After Epilepsy Drug Licensing Deal", "topics": [], "summary": "", "age_days": 2.8, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/markets/stocks/articles/biohaven-shares-rise-epilepsy-drug-182910055.html", "source_name": "MT Newswires", "published_at": "2026-08-26T18:29:10+00:00", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 75.6, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.042923, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "26 Aug 2026 18:29", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://finance.yahoo.com/m/3d441be9-13a0-30c9-8fdb-a3c36bebaa34/biohaven-shares-climb-7%25.html", "tier": "direct", "title": "Biohaven shares climb 7% after signing major SK Biopharmaceuticals licensing deal", "topics": [], "summary": "", "age_days": 3.1, "is_stale": false, "sentiment": "positive", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/m/3d441be9-13a0-30c9-8fdb-a3c36bebaa34/biohaven-shares-climb-7%25.html", "source_name": "InvestorsHub", "published_at": "2026-08-26T12:28:24+00:00", "tone_signals": ["Positive market reaction", "Large positive market reaction"], "company_focus": 0.78, "freshness_pct": 73.8, "sentiment_pct": 67, "evidence_basis": "headline_only", "evidence_share": 10.7, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.102751, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 78, "evidence_strength": 54, "published_display": "26 Aug 2026 12:28", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "10.7"}, {"url": "https://finance.yahoo.com/m/1e91c2b4-76e0-3830-b47e-a53a4ff0d9f6/biohaven-trades-cash-for.html", "tier": "direct", "title": "Biohaven trades cash for \u2018upside\u2019 with $795M epilepsy drug deal", "topics": [], "summary": "", "age_days": 3.1, "is_stale": false, "sentiment": "positive", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/m/1e91c2b4-76e0-3830-b47e-a53a4ff0d9f6/biohaven-trades-cash-for.html", "source_name": "BioPharma Dive", "published_at": "2026-08-26T11:17:41+00:00", "tone_signals": ["Positive financial language"], "company_focus": 0.78, "freshness_pct": 73.4, "sentiment_pct": 57, "evidence_basis": "headline_only", "evidence_share": 6.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.057776, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 78, "evidence_strength": 42, "published_display": "26 Aug 2026 11:17", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "6"}, {"url": "https://finance.yahoo.com/healthcare/articles/biohaven-sk-biopharmaceuticals-enter-strategic-060100876.html", "tier": "direct", "title": "Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy", "topics": ["Balance Sheet", "Biopharmaceuticals", "Epilepsy", "Licensing Agreement"], "summary": "SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim. Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026. It is designed to offer an easy-to-use, once-daily oral treatment without the need for titration and a low incidence of burdens", "age_days": 3.3, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/biohaven-sk-biopharmaceuticals-enter-strategic-060100876.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-26T06:01:00+00:00", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 62.9, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.036376, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "26 Aug 2026 06:01", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMingJBVV95cUxOUGZHYWxNaGFacDdSUXNxQTQ2a0l4cTRjdm1KNURaNlk2V3RXaHBnNlIweUtRaGsta242THBqaHBpbjgtd2E3SmJYWi1FcFBxaW4wSGg5NFpCa2VpXzN1WnVWNFJudFBIcGJRTmNVbUl5elFzbnFWdVU2S2dDNFVBNlJyRFI1NTc5bHhLWlRCM25zVm1hUUhYbVotbDNCWWQ1RmxJbGU2Z2x6WnNVcEdNYUJJaElyRkpNRUZobEJMZklvVFFJU1ZpR1cwMm1KRjFkd1dieGx0UWFMMW15WmQ3d2NtVlgtOU13V1g5UC1fVkJkbFQ5czZDTEp5SDUtMzFIanRyYjd0OFZHSWt2WTBGR2JwUGNwYTFHT080cW9n?oc=5", "tier": "direct", "title": "Biohaven (BHVN) Financial Update: The Available Earnings Metric Delivers a Miss for This Review; Post-Earnings: Shares Move 5.12% Higher in the Latest Session - Pre-Earnings Drift", "topics": [], "summary": "", "age_days": 3.4, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMingJBVV95cUxOUGZHYWxNaGFacDdSUXNxQTQ2a0l4cTRjdm1KNURaNlk2V3RXaHBnNlIweUtRaGsta242THBqaHBpbjgtd2E3SmJYWi1FcFBxaW4wSGg5NFpCa2VpXzN1WnVWNFJudFBIcGJRTmNVbUl5elFzbnFWdVU2S2dDNFVBNlJyRFI1NTc5bHhLWlRCM25zVm1hUUhYbVotbDNCWWQ1RmxJbGU2Z2x6WnNVcEdNYUJJaElyRkpNRUZobEJMZklvVFFJU1ZpR1cwMm1KRjFkd1dieGx0UWFMMW15WmQ3d2NtVlgtOU13V1g5UC1fVkJkbFQ5czZDTEp5SDUtMzFIanRyYjd0OFZHSWt2WTBGR2JwUGNwYTFHT080cW9n?oc=5", "source_name": "vinanet.vn", "published_at": "2026-08-26T04:48:41+00:00", "tone_signals": ["Missed expectations"], "company_focus": 1.0, "freshness_pct": 62.5, "sentiment_pct": 25, "evidence_basis": "headline_only", "evidence_share": 13.9, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.133547, "influence_label": "High", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 64, "published_display": "26 Aug 2026 04:48", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "13.9"}, {"url": "https://ca.investing.com/news/stock-market-news/biohaven-yale-win-4m-judgment-in-trade-secret-case-93CH-4816327", "tier": "direct", "title": "Biohaven, Yale win $4M judgment in trade secret case By Investing.com", "topics": ["Finance", "Life Sciences"], "summary": "Biohaven Ltd. and Yale University have been awarded a combined $4 million judgment in a trade secret misappropriation and breach of contract lawsuit against Avilar Therapeutics, Inc. and RA Capital Management GP, LLC. The judgment follows a jury verdict which found that RA Capital and Avilar willfully and maliciously misappropriated Yale's MODA targeted protein degradation platform trade secret and that RA Capital breached a 2019 confidentiality agreement with Yale. Yale received $2 million for the breach of contract and $1 million each from both Biohaven and Yale for trade secret misappropriation.", "age_days": 3.7, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://ca.investing.com/news/stock-market-news/biohaven-yale-win-4m-judgment-in-trade-secret-case-93CH-4816327", "source_name": "Investing.com Canada", "published_at": "2026-08-25T20:44:51+00:00", "tone_signals": ["Legal or regulatory risk"], "company_focus": 1.0, "freshness_pct": 69.1, "sentiment_pct": 45, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.123147, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "25 Aug 2026 20:44", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.prnewswire.com/news-releases/federal-court-enters-judgment-confirming-ra-capital-and-avilar-therapeutics-willfully-and-maliciously-misappropriated-trade-secret-developed-at-yale-formalizing-4-million-award-to-biohaven-and-yale-university-302859834.html", "tier": "direct", "title": "Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University", "topics": ["Finance", "Life Sciences"], "summary": "A U.S. District Court in Delaware has formalized a $4 million award to Biohaven Ltd. and Yale University, ruling that RA Capital Management GP, LLC and Avilar Therapeutics, Inc. willfully and maliciously misappropriated a trade secret related to Yale's \"MODA\" protein degradation platform. The judgment confirms a jury's verdict, with $2 million awarded to Yale for RA Capital's breach of contract and $1 million each to Yale and Biohaven for trade secret misappropriation. Biohaven had licensed the MODA platform from Yale and pursued litigation after RA Capital allegedly used confidential information to establish a competing company, Avilar, rather than partnering with Yale.", "age_days": 3.7, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "press_release", "source_link": "https://www.prnewswire.com/news-releases/federal-court-enters-judgment-confirming-ra-capital-and-avilar-therapeutics-willfully-and-maliciously-misappropriated-trade-secret-developed-at-yale-formalizing-4-million-award-to-biohaven-and-yale-university-302859834.html", "source_name": "PR Newswire", "published_at": "2026-08-25T20:44:51", "tone_signals": ["Contract or approval won"], "company_focus": 1.0, "freshness_pct": 69.1, "sentiment_pct": 55, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.105023, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "25 Aug 2026 20:44", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxOeVVMVU5UaGVvb3pnWWpMVk81S0ZaUU1BV19ISFdvNzFoUVZlSFhDbVkzTC0xbS1OSi1SQXY4Vi1PeXBkSHRiZ3IyU0RaMWJraVJ1ajRjTTZwakk1NkYwcWpDeUdiZHpMTGo0c2FhcEEwNFhJU0FYTUpna0xIcHJ4ZHU4RE9Pd0ZVWlpsNEs0SC1JZ25TbVBPVFlHamlIczU4dFNXSURhUWZRMDduMlFWd0VHUEhnR3hxa2RDZExLRWU4MmJHbERnVUh1cTVBSlZLR2xXT21BSUJsdk1QcFVHSVRpV0ZXWHEtanZwczhiMHhKS19YU0k4NFZmc3RnSEc0a2RUc3NzM19lZlg1RDRVNU9WYlNEdlc3U0NwMTNzWHcyLS1kdDljNXl3VnM?oc=5", "tier": "direct", "title": "BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout", "topics": [], "summary": "", "age_days": 4.0, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMirAJBVV95cUxOeVVMVU5UaGVvb3pnWWpMVk81S0ZaUU1BV19ISFdvNzFoUVZlSFhDbVkzTC0xbS1OSi1SQXY4Vi1PeXBkSHRiZ3IyU0RaMWJraVJ1ajRjTTZwakk1NkYwcWpDeUdiZHpMTGo0c2FhcEEwNFhJU0FYTUpna0xIcHJ4ZHU4RE9Pd0ZVWlpsNEs0SC1JZ25TbVBPVFlHamlIczU4dFNXSURhUWZRMDduMlFWd0VHUEhnR3hxa2RDZExLRWU4MmJHbERnVUh1cTVBSlZLR2xXT21BSUJsdk1QcFVHSVRpV0ZXWHEtanZwczhiMHhKS19YU0k4NFZmc3RnSEc0a2RUc3NzM19lZlg1RDRVNU9WYlNEdlc3U0NwMTNzWHcyLS1kdDljNXl3VnM?oc=5", "source_name": "Stocktwits", "published_at": "2026-08-25T13:30:03+00:00", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 24.7, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.010141, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "25 Aug 2026 13:30", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxQQmN1eFVJUGlhX0NRQW5uX0ZUZUczNWtFeTl2SFFaWkFDRGs1NHg4UVVNdVBCa19zQzBfQ0JjSEZGc3hqMFVjVFpjbmh3cG1hTUxWQ3BSYmNMTktGWnhJaTA4RkZZb29rbXNpeV9jUkZCaUk5dWg4YWF5UG5UUi0xS0x1djRzQVRWdl9iRDlwQ3ZtQ3NqaVJZQWlUVXEydE1qejRkUVh4NnVPNkdrM21lYTB3TXl3YV9iWFpVa3kybXUtRFI1emI2NzJxOGJMd085a1pLMFpZN3RmVDBzSEo3QkUzRjlTam5YalpNMWg1VzFZeVVvbUtDZkhIWldQZmlEcFFqdHhRQ2xkQQ?oc=5", "tier": "direct", "title": "Biohaven (BHVN) Q2 2026 Earnings: The Bottom-Line Figure Trails Its Comparison on the Day; Share Response", "topics": [], "summary": "", "age_days": 5.1, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiigJBVV95cUxQQmN1eFVJUGlhX0NRQW5uX0ZUZUczNWtFeTl2SFFaWkFDRGs1NHg4UVVNdVBCa19zQzBfQ0JjSEZGc3hqMFVjVFpjbmh3cG1hTUxWQ3BSYmNMTktGWnhJaTA4RkZZb29rbXNpeV9jUkZCaUk5dWg4YWF5UG5UUi0xS0x1djRzQVRWdl9iRDlwQ3ZtQ3NqaVJZQWlUVXEydE1qejRkUVh4NnVPNkdrM21lYTB3TXl3YV9iWFpVa3kybXUtRFI1emI2NzJxOGJMd085a1pLMFpZN3RmVDBzSEo3QkUzRjlTam5YalpNMWg1VzFZeVVvbUtDZkhIWldQZmlEcFFqdHhRQ2xkQQ?oc=5", "source_name": "vinanet.vn", "published_at": "2026-08-24T12:32:11+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 49.5, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.040733, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "24 Aug 2026 12:32", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.sahmcapital.com/news/content/is-biohaven-bhvn-undervalued-following-its-latest-earnings-loss-improvement-2026-08-23", "tier": "direct", "title": "Is Biohaven (BHVN) Undervalued Following Its Latest Earnings Loss Improvement?", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "summary": "Biohaven (BHVN) reported improved Q2 2026 earnings, reducing its net loss to US$137.31 million. While the stock's price-to-book ratio of 171.2x suggests overvaluation compared to industry averages, a Discounted Cash Flow (DCF) model from Simply Wall St indicates the shares might be significantly undervalued at $13.85, estimating a future cash flow value of $53.83 per share. The article highlights the conflicting valuation perspectives, urging investors to consider both the risks of a loss-making biotech and the potential of its pipeline.", "age_days": 5.2, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.sahmcapital.com/news/content/is-biohaven-bhvn-undervalued-following-its-latest-earnings-loss-improvement-2026-08-23", "source_name": "Sahm", "published_at": "2026-08-24T09:16:31+00:00", "tone_signals": ["Positive valuation view", "Improving financial comparison"], "company_focus": 1.0, "freshness_pct": 48.6, "sentiment_pct": 57, "evidence_basis": "archived_article", "evidence_share": 10.2, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.098656, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 43, "published_display": "24 Aug 2026 09:16", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "10.2"}, {"url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/why-biohaven-bhvn-is-down-91-after-reporting-narrower-q2-and", "tier": "direct", "title": "Why Biohaven (BHVN) Is Down 9.1% After Reporting Narrower Q2 and H1 Net Losses", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Biohaven Ltd. reported narrower net losses for Q2 and H1 2026, with Q2 losses at US$137.31 million and H1 losses at US$267.84 million. Despite this, the company's shares dropped 9.1%, and concerns remain regarding its cash burn, reliance on future capital raises, and whether its significant pipeline can justify current spending. Investors are advised to consider various perspectives and the company's financial health before making investment decisions.", "age_days": 7.0, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/why-biohaven-bhvn-is-down-91-after-reporting-narrower-q2-and", "source_name": "Simply Wall Street", "published_at": "2026-08-22T13:13:56+00:00", "tone_signals": ["Negative market reaction", "Large negative market reaction"], "company_focus": 1.0, "freshness_pct": 37.7, "sentiment_pct": 34, "evidence_basis": "archived_article", "evidence_share": 9.5, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.091871, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 50, "published_display": "22 Aug 2026 13:13", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "9.5"}, {"url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOLVRZeFg4c3ZBZ0RtRkxsaUVYQm4tQ2JzME81NnQ0bWFxckJISE40YW1FSXBjWS0zYVoxdTA4TmVFbDNWek5ZcFdQaS01V3BpaDd3RFhaTXREbWQweHI3d0R4czNyUlJ5dW16N0VlLVNsMGdkRnFkTE9SWndfcDh1Y1dndjR3SkdRM0VZMU9iMklrLWpqaVBaWnJnUlcxUWc?oc=5", "tier": "direct", "title": "Price to earnings forward of Biohaven Ltd. \u2013 NYSE:BHVN", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "This article provides financial information for Biohaven Ltd. (NYSE: BHVN), specifically focusing on its forward price-to-earnings ratio. The content appears to be a page from a financial data platform, displaying the company's ticker, exchange, and a placeholder for the \"Price to earnings forward\" value.", "age_days": 7.5, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOLVRZeFg4c3ZBZ0RtRkxsaUVYQm4tQ2JzME81NnQ0bWFxckJISE40YW1FSXBjWS0zYVoxdTA4TmVFbDNWek5ZcFdQaS01V3BpaDd3RFhaTXREbWQweHI3d0R4czNyUlJ5dW16N0VlLVNsMGdkRnFkTE9SWndfcDh1Y1dndjR3SkdRM0VZMU9iMklrLWpqaVBaWnJnUlcxUWc?oc=5", "source_name": "TradingView", "published_at": "2026-08-22T01:37:32+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 35.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.033821, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "22 Aug 2026 01:37", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPR1BZQnByN2N5dFNuaWZsbnFWNlBHTUd3MXNrTHh3S2s4TWYxbnpZeFZiT3RFbFhISndtdDBhMkd6U2hkLWxtVXYxa19lQ0cxNTlVaDJDcXFtdHZpTVc1Y1A5bU9ObVhsLVZCSzBYajVXTkE5aVlQX2xkUnFOQVZlMEZManFaVnpwXy1zMUI0RURCbjg2UWtLWVFTODdlWkI3MUV3b0lqbGk3UXhJeXc?oc=5", "tier": "direct", "title": "HC Wainwright Decreases Earnings Estimates for Biohaven", "topics": [], "summary": "", "age_days": 8.1, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPR1BZQnByN2N5dFNuaWZsbnFWNlBHTUd3MXNrTHh3S2s4TWYxbnpZeFZiT3RFbFhISndtdDBhMkd6U2hkLWxtVXYxa19lQ0cxNTlVaDJDcXFtdHZpTVc1Y1A5bU9ObVhsLVZCSzBYajVXTkE5aVlQX2xkUnFOQVZlMEZManFaVnpwXy1zMUI0RURCbjg2UWtLWVFTODdlWkI3MUV3b0lqbGk3UXhJeXc?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-21T12:45:30+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 32.7, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.031398, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "21 Aug 2026 12:45", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNSko4T1N6VU5mZFppMVNMbnRGdXUtZ0NPaU85N0ZyYWpOZEVUTW1EemtNdkg1bng1RHdNN01PMkEtMFk0a0c4anNSYzJ1OThHQmhOdWJCYmU3QjdHTktWM296QW8xY0MzbzM1V1pQRHlnTmx5SUZqcmFVTHd3UUJuWWx1NDhWWkgwbDg1WW9GcmsyUXBUb2FLNXBLMGVGeEJUbDJBcHZleG5QaXliWThySWNLcG9ObWhCOHBiX283VjExLTVrNWM5ZUE2RmFEUQ?oc=5", "tier": "direct", "title": "Biohaven Ltd. (NYSE:BHVN) Receives Consensus Rating of \"Moderate Buy\" from Brokerages", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "summary": "Biohaven Ltd. (NYSE:BHVN) has received a \"Moderate Buy\" consensus rating from seventeen research firms, with an average 12-month price target of $21.75. The company's shares opened at $13.59, and it recently reported a quarterly EPS of negative $0.91, missing the consensus estimate. Institutional investors hold 88.78% of the stock, and analysts anticipate a full-year loss of approximately $3.11 per share.", "age_days": 10.3, "is_stale": false, "sentiment": "neutral", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNSko4T1N6VU5mZFppMVNMbnRGdXUtZ0NPaU85N0ZyYWpOZEVUTW1EemtNdkg1bng1RHdNN01PMkEtMFk0a0c4anNSYzJ1OThHQmhOdWJCYmU3QjdHTktWM296QW8xY0MzbzM1V1pQRHlnTmx5SUZqcmFVTHd3UUJuWWx1NDhWWkgwbDg1WW9GcmsyUXBUb2FLNXBLMGVGeEJUbDJBcHZleG5QaXliWThySWNLcG9ObWhCOHBiX283VjExLTVrNWM5ZUE2RmFEUQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-19T06:32:50+00:00", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "freshness_pct": 9.2, "sentiment_pct": 46, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.009332, "influence_label": "None", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "19 Aug 2026 06:32", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.marketbeat.com/instant-alerts/filing-biohaven-ltd-bhvn-shares-bought-by-quantinno-capital-management-lp-2026-08-16", "tier": "direct", "title": "Biohaven Ltd. $BHVN Shares Bought by Quantinno Capital Management LP", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "summary": "Quantinno Capital Management LP significantly increased its stake in Biohaven Ltd. (BHVN) by 190% in the first quarter, bringing its total to 121,554 shares. Several other institutional investors also expanded their positions, contributing to the high institutional ownership of 88.78%. Despite a reported quarterly loss of $0.91 per share, analysts maintain a \"Moderate Buy\" rating with a consensus price target of $21.75, considerably higher than the stock's recent trading price.", "age_days": 13.1, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/instant-alerts/filing-biohaven-ltd-bhvn-shares-bought-by-quantinno-capital-management-lp-2026-08-16", "source_name": "MarketBeat", "published_at": "2026-08-16T12:10:10+00:00", "tone_signals": ["Institutional or insider buying"], "company_focus": 1.0, "freshness_pct": 16.3, "sentiment_pct": 58, "evidence_basis": "archived_article", "evidence_share": 3.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.029284, "influence_label": "Medium", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 36, "published_display": "16 Aug 2026 12:10", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "3"}, {"url": "https://news.google.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?oc=5", "tier": "direct", "title": "Biohaven (BHVN) Could Be 73% Undervalued As Regeneron Deal Expands", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Biohaven (BHVN) is gaining attention after expanding its oncology collaboration with Regeneron Pharmaceuticals. Despite a recent slight easing in share price, the stock shows strong 90-day returns, contrasting with weaker long-term performance. A discounted cash flow (DCF) model by Simply Wall St suggests Biohaven could be 73% undervalued, estimating a fair value of $54.53 against its current trading price of $14.64, although its high P/B ratio indicates significant valuation risk.", "age_days": 13.8, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-08-15T18:40:36+00:00", "tone_signals": ["Positive valuation view"], "company_focus": 1.0, "freshness_pct": 14.7, "sentiment_pct": 70, "evidence_basis": "archived_article", "evidence_share": 4.1, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.039094, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 49, "published_display": "15 Aug 2026 18:40", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "4.1"}, {"url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/is-biohavens-narrowing-losses-and-ai-board-hire-altering-the", "tier": "direct", "title": "Is Biohaven\u2019s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)?", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences", "Technology"], "summary": "Biohaven Ltd. reported narrowing losses in Q2 2026, with a net loss of US$137.31 million, and appointed AI-focused investor John Yetimoglu to its Board. Despite these developments, the company still faces significant financial risk due to zero revenue, heavy ongoing losses, and a short cash runway, with investors needing to consider future funding and potential dilution. The article suggests that while the AI appointment aligns with Biohaven's data-driven R&D, it doesn't immediately alter the key value drivers of its epilepsy and MoDE degrader programs.", "age_days": 14.6, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/is-biohavens-narrowing-losses-and-ai-board-hire-altering-the", "source_name": "Simply Wall Street", "published_at": "2026-08-14T23:10:10+00:00", "tone_signals": ["Dilution risk"], "company_focus": 1.0, "freshness_pct": 13.2, "sentiment_pct": 33, "evidence_basis": "archived_article", "evidence_share": 3.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.029046, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 45, "published_display": "14 Aug 2026 23:10", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "3"}, {"url": "https://finance.yahoo.com/healthcare/articles/biohaven-bhvn-latest-regeneron-pharmaceuticals-222352923.html", "tier": "direct", "title": "Is Biohaven (BHVN)\u2019s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?", "topics": ["Biotech", "Clinical Trials", "Earnings", "Net Income", "Pharma", "Price Target"], "summary": "Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron's cemiplimab (Libtayo) in patients with solid tumors. BHV-1530's novel topoisomerase I (TopoIx) payload generates immunogenic cell death and triggers antitumor immune responses, creating a compelling rationale when paired with checkpoint inhibition. Building on an earlier agreement for BHV-1510, a TROP2-d", "age_days": 14.7, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/biohaven-bhvn-latest-regeneron-pharmaceuticals-222352923.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-14T22:23:52+00:00", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 13.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.007576, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "14 Aug 2026 22:23", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.stocktitan.net/sec-filings/BHVN/schedule-13g-biohaven-ltd-passive-investment-disclosure-5-c85f0e31a822.html", "tier": "direct", "title": "Woodline Partners (BHVN) discloses 5.1% beneficial stake in Biohaven", "topics": ["Financial Markets", "Life Sciences"], "summary": "Woodline Partners LP has reported a beneficial ownership of 5.1% in Biohaven Ltd., amounting to 7,660,280 Common Shares. This ownership grants Woodline Partners sole voting and dispositive power over these shares, which are held through Woodline Master Fund LP and Woodline Spire Master Fund LP. The stake is based on Biohaven's 150,560,990 Common Shares outstanding as of April 30, 2026.", "age_days": 15.0, "is_stale": false, "sentiment": "neutral", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/BHVN/schedule-13g-biohaven-ltd-passive-investment-disclosure-5-c85f0e31a822.html", "source_name": "Stock Titan", "published_at": "2026-08-14T15:12:26+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 22.7, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.019642, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "14 Aug 2026 15:12", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-acquires-new-position-in-biohaven-ltd-bhvn-2026-08-14", "tier": "direct", "title": "Renaissance Technologies LLC Acquires New Position in Biohaven Ltd. $BHVN", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Renaissance Technologies LLC has acquired a new position in Biohaven Ltd. (NYSE:BHVN), purchasing 160,952 shares valued at approximately $1.36 million. This move comes as institutional investors collectively own 88.78% of Biohaven, with several major funds significantly increasing their stakes. Despite missing quarterly EPS expectations, analysts maintain a \"Moderate Buy\" rating with an average price target of $21.75 for Biohaven.", "age_days": 15.1, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-acquires-new-position-in-biohaven-ltd-bhvn-2026-08-14", "source_name": "MarketBeat", "published_at": "2026-08-14T11:12:26", "tone_signals": ["Institutional or insider buying"], "company_focus": 1.0, "freshness_pct": 12.3, "sentiment_pct": 60, "evidence_basis": "archived_article", "evidence_share": 2.5, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.024319, "influence_label": "Medium", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 38, "published_display": "14 Aug 2026 11:12", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "2.5"}, {"url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxOUFhDdC1TOHlCdENVOUFNYThrLWJUajdMWDFKQlhYeXFRdXowV0s1MEdaQXprZUhsNmVDZm1USHR5Y1loWDluSk5GMEdMb2lCajN1bGc1WjNZaDFQMF85Z1R6VXl2ekZFa3FpRFhNTlQ3ZFZhTkZiQURQUXEyYVVoUGlCVEtqX1JsdzNPLWZETnFlbHlHT2Qxa2NSNXFXOGp2TFI4MjZLWGJZeWdyRnBrejNJTUpDZUdWT1JYSVYwUGhLUUNmY2JRYkRHSlRKSGxQZ2xTa3ZpSVZ4QTZqMXdKamt4eF9tbU1pMmpKRERVLWE?oc=5", "tier": "direct", "title": "Bank of America Securities Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN)", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Bank of America Securities has reiterated a Buy rating on Biohaven Ltd. (BHVN) with a price target of $11.00, despite the stock closing higher at $14.54. Analyst Dina Ramadane, who covers the Healthcare sector, has a 61.54% success rate on her recommendations. The broader analyst consensus for Biohaven Ltd. is a Moderate Buy with an average price target of $16.33.", "age_days": 17.3, "is_stale": false, "sentiment": "positive", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxOUFhDdC1TOHlCdENVOUFNYThrLWJUajdMWDFKQlhYeXFRdXowV0s1MEdaQXprZUhsNmVDZm1USHR5Y1loWDluSk5GMEdMb2lCajN1bGc1WjNZaDFQMF85Z1R6VXl2ekZFa3FpRFhNTlQ3ZFZhTkZiQURQUXEyYVVoUGlCVEtqX1JsdzNPLWZETnFlbHlHT2Qxa2NSNXFXOGp2TFI4MjZLWGJZeWdyRnBrejNJTUpDZUdWT1JYSVYwUGhLUUNmY2JRYkRHSlRKSGxQZ2xTa3ZpSVZ4QTZqMXdKamt4eF9tbU1pMmpKRERVLWE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-08-12T07:00:00+00:00", "tone_signals": ["Buy Rating"], "company_focus": 1.0, "freshness_pct": 1.8, "sentiment_pct": 72, "evidence_basis": "archived_article", "evidence_share": 0.4, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.003916, "influence_label": "Medium", "event_confidence": 69, "company_focus_pct": 100, "evidence_strength": 46, "published_display": "12 Aug 2026 07:00", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.4"}, {"url": "https://m.investing.com/news/analyst-ratings/biohaven-pharma-stock-price-target-raised-to-23-by-rbc-capital-93CH-4852142?ampMode=1", "tier": "direct", "title": "Biohaven Pharma stock price target raised to $23 by RBC Capital", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "RBC Capital has raised its price target for Biohaven Pharma (NYSE:BHVN) to $23 from $22, maintaining an Outperform rating, following the company's second-quarter 2026 earnings report. The firm highlights potential opportunities in troriluzole and degrader data, estimating a more than $4 billion market by 2035, and anticipates success in the near-term Kv7 readout. Despite some elevated spending and concerns about cash burn, the pipeline is deemed attractive, and the company is progressing with other trials like RISE3 for epilepsy and a Phase 3 trial for Graves\u2019 disease.", "age_days": 18.0, "is_stale": false, "sentiment": "positive", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://m.investing.com/news/analyst-ratings/biohaven-pharma-stock-price-target-raised-to-23-by-rbc-capital-93CH-4852142?ampMode=1", "source_name": "Investing.com", "published_at": "2026-08-11T14:44:42+00:00", "tone_signals": ["Analyst upgrade"], "company_focus": 1.0, "freshness_pct": 1.6, "sentiment_pct": 75, "evidence_basis": "archived_article", "evidence_share": 0.5, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.005033, "influence_label": "Medium", "event_confidence": 96, "company_focus_pct": 100, "evidence_strength": 49, "published_display": "11 Aug 2026 14:44", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.5"}, {"url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOd0s0Z3BLWGYxUmdSeGt1N1RIQkNSZzM5UXl4V3BBS0xRUXZ3MVlzZGdJcUFlZVMxT1BPbVd4alVLVTJVRWVwbUNxaXBaNkhJelJfNVkxNTYyWExYX2lVUG9Pc1RDUXBrUElYb05DVFBvRzR4eFZXTGlpejNzZTNvdDBSSE9KR2JHbGdscl9yZ1BPekFXSU9PcHM1cUVsN2ln?oc=5", "tier": "direct", "title": "Biohaven (BHVN) Holds Near Key Support After Modest Pullback - Pre-Earnings Momentum", "topics": [], "summary": "", "age_days": 18.3, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOd0s0Z3BLWGYxUmdSeGt1N1RIQkNSZzM5UXl4V3BBS0xRUXZ3MVlzZGdJcUFlZVMxT1BPbVd4alVLVTJVRWVwbUNxaXBaNkhJelJfNVkxNTYyWExYX2lVUG9Pc1RDUXBrUElYb05DVFBvRzR4eFZXTGlpejNzZTNvdDBSSE9KR2JHbGdscl9yZ1BPekFXSU9PcHM1cUVsN2ln?oc=5", "source_name": "vinanet.vn", "published_at": "2026-08-11T07:00:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.2, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 9.4e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Aug 2026 07:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.stocktitan.net/sec-filings/BHVN/10-q-biohaven-ltd-quarterly-earnings-report-6b7da5e6453e.html", "tier": "direct", "title": "Biohaven (NYSE: BHVN) reports $267.8M H1 2026 loss and $267.9M in liquidity", "topics": ["Earnings", "Life Sciences"], "summary": "Biohaven Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company, reported a net loss of $267.8 million for the first half of 2026, primarily due to $204.6 million in research and development expenses. The company maintains liquidity with $267.9 million in cash, cash equivalents, and marketable securities, which management expects to fund operations for at least one year. Biohaven is focused on advancing its R&D portfolio across immunology, obesity, neuroscience, and oncology, including key clinical programs such as Kv7 ion channel modulation for epilepsy and Molecular Degrader of Extracellular Proteins (MoDE) for immunological diseases.", "age_days": 18.3, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/BHVN/10-q-biohaven-ltd-quarterly-earnings-report-6b7da5e6453e.html", "source_name": "Stock Titan", "published_at": "2026-08-11T06:15:38+00:00", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "freshness_pct": 7.9, "sentiment_pct": 41, "evidence_basis": "archived_article", "evidence_share": 1.2, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.011475, "influence_label": "Low", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 34, "published_display": "11 Aug 2026 06:15", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "1.2"}, {"url": "https://www.marketbeat.com/instant-alerts/biohaven-nysebhvn-posts-quarterly-earnings-results-misses-estimates-by-002-eps-2026-08-10", "tier": "direct", "title": "Biohaven (NYSE:BHVN) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Biohaven (NYSE:BHVN) announced its quarterly earnings, reporting a loss of $0.78 per share, which missed analysts' consensus estimates by $0.02. Following the announcement, shares of Biohaven dropped 0.5% to $14.58. Despite the earnings miss, analyst sentiment for Biohaven remains a \"Moderate Buy\" with an average price target of $21.62.", "age_days": 18.6, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/instant-alerts/biohaven-nysebhvn-posts-quarterly-earnings-results-misses-estimates-by-002-eps-2026-08-10", "source_name": "MarketBeat", "published_at": "2026-08-10T23:15:38+00:00", "tone_signals": ["Missed expectations", "Negative market reaction", "Large negative market reaction"], "company_focus": 1.0, "freshness_pct": 7.6, "sentiment_pct": 16, "evidence_basis": "archived_article", "evidence_share": 3.2, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.030842, "influence_label": "High", "event_confidence": 93, "company_focus_pct": 100, "evidence_strength": 63, "published_display": "10 Aug 2026 23:15", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "3.2"}, {"url": "https://www.marketbeat.com/instant-alerts/filing-biohaven-ltd-bhvn-shares-purchased-by-the-manufacturers-life-insurance-company-2026-08-10", "tier": "direct", "title": "Biohaven Ltd. $BHVN Shares Purchased by The Manufacturers Life Insurance Company", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "The Manufacturers Life Insurance Company increased its stake in Biohaven Ltd. (NYSE:BHVN) by 52.5% in Q1, now owning 202,975 shares valued at $1.72 million. Other institutional investors also significantly increased their holdings, with hedge funds and institutional investors collectively owning 88.78% of the stock. Analysts currently rate Biohaven as a \"Moderate Buy\" with an average price target of $21.62.", "age_days": 18.8, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/instant-alerts/filing-biohaven-ltd-bhvn-shares-purchased-by-the-manufacturers-life-insurance-company-2026-08-10", "source_name": "MarketBeat", "published_at": "2026-08-10T20:09:36+00:00", "tone_signals": ["Institutional or insider buying"], "company_focus": 1.0, "freshness_pct": 7.4, "sentiment_pct": 60, "evidence_basis": "archived_article", "evidence_share": 1.5, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.014709, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 37, "published_display": "10 Aug 2026 20:09", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "1.5"}, {"url": "https://kalkinemedia.com/us/news/announcements/biohaven-ltd-announces-q2-2026-financial-results-highlighting-reduced-losses-and-rd-spending", "tier": "direct", "title": "Biohaven Ltd. Announces Q2 2026 Financial Results Highlighting Reduced Losses and R&D Spending", "topics": ["Earnings", "Life Sciences"], "summary": "Biohaven Ltd. has filed its Q2 2026 financial report, revealing continued operating losses but also a reduction in research and development spending compared to the previous year. This report covers the three- and six-month periods ending June 30, 2026. The full details are available via an SEC Form 10-Q filing.", "age_days": 19.0, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://kalkinemedia.com/us/news/announcements/biohaven-ltd-announces-q2-2026-financial-results-highlighting-reduced-losses-and-rd-spending", "source_name": "Kalkine Media", "published_at": "2026-08-10T14:16:00+00:00", "tone_signals": ["Loss narrowed"], "company_focus": 1.0, "freshness_pct": 7.2, "sentiment_pct": 66, "evidence_basis": "archived_article", "evidence_share": 1.5, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.014322, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 42, "published_display": "10 Aug 2026 14:16", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "1.5"}, {"url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxORUFxb2RXeWJiVjlxVVozSTdvQS1mLVZaM2lGZ2d2ZHpWOHlkcmMzbWZadGNoZWg5M184RUxFbHI1bW5QUHEwYjdMODBaUWxacWZfZmJzSVVrTGZSU1pnQ2ozQ0EwRmEyWmVJZEgxdENrX2xTNzVSVWw4TVdDb1U2OHBvZDdtcGRWeXl5RGZTbGZGTzk3WXhHRlRCYi1BeHVONGVOemVfRHUzempyQm5TWXFJZEtfeVZRR0p6SDdLWFJ1elRobTd1akRjTFdtcFZDUllSVDNob1V6NTA?oc=5", "tier": "direct", "title": "Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results", "topics": ["AUTOIMMUNE-DISEASES", "Autoimmune Diseases", "BIOPHARMA", "Biopharma", "CLINICAL-TRIALS", "Clinical Trials"], "summary": "First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed, Phase 3 trial underway Positive clinical biomarker and patient data presented from Biohaven's extracellular degrader platform demonstrated deep, rapid, selective lowering of disease-driving antibodies with BHV-1300 in Graves' disease and BHV-1400 IgA Nephropathy, supporting advancement toward multiple registrational programs. Initiated pivotal Phase 3 study for BHV-1300 in Graves' disease with plans to initiate pivotal Phase 3 study for", "age_days": 19.3, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "press_release", "source_link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxORUFxb2RXeWJiVjlxVVozSTdvQS1mLVZaM2lGZ2d2ZHpWOHlkcmMzbWZadGNoZWg5M184RUxFbHI1bW5QUHEwYjdMODBaUWxacWZfZmJzSVVrTGZSU1pnQ2ozQ0EwRmEyWmVJZEgxdENrX2xTNzVSVWw4TVdDb1U2OHBvZDdtcGRWeXl5RGZTbGZGTzk3WXhHRlRCYi1BeHVONGVOemVfRHUzempyQm5TWXFJZEtfeVZRR0p6SDdLWFJ1elRobTd1akRjTFdtcFZDUllSVDNob1V6NTA?oc=5", "source_name": "PR Newswire", "published_at": "2026-08-10T07:00:00+00:00", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "freshness_pct": 6.9, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.008428, "influence_label": "None", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "10 Aug 2026 07:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://m.investing.com/news/earnings/biohaven-earnings-set-to-show-cash-burn-ahead-of-epilepsy-data-93CH-4847742?ampMode=1", "tier": "direct", "title": "Biohaven earnings set to show cash burn ahead of epilepsy data", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Biohaven Pharmaceutical Holding Co Ltd is expected to report its second-quarter earnings, with analysts forecasting a narrower loss of 75 cents per share. Investors will be closely watching the company's cash burn rate and updates on its epilepsy drug candidate, opakalim, which has topline results expected in the second half of 2026. The stock faces skepticism from some analysts due to competitive concerns and cash runway, while others maintain a positive outlook.", "age_days": 20.0, "is_stale": false, "sentiment": "positive", "event_type": "liquidity", "tier_label": "Direct company coverage", "event_label": "Balance sheet", "source_kind": "publisher", "source_link": "https://m.investing.com/news/earnings/biohaven-earnings-set-to-show-cash-burn-ahead-of-epilepsy-data-93CH-4847742?ampMode=1", "source_name": "Investing.com", "published_at": "2026-08-09T13:10:06+00:00", "tone_signals": ["Beat expectations"], "company_focus": 1.0, "freshness_pct": 13.7, "sentiment_pct": 76, "evidence_basis": "archived_article", "evidence_share": 5.9, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.056734, "influence_label": "Medium", "event_confidence": 77, "company_focus_pct": 100, "evidence_strength": 54, "published_display": "09 Aug 2026 13:10", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "5.9"}, {"url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTFBELVhFeFlqNWozQXltSXhHSEl2OFczc1ZnLS03MHBfYlJ5X0ZsUEt4M2FyZk1BdFZPOG5PVDlPaWRVejdoYU1WcXJpR1gwenBJM3RqTzV4dW81ckI3RUVKaXFUWnNNQQ?oc=5", "tier": "direct", "title": "Biohaven Ltd (BHVN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "topics": [], "summary": "", "age_days": 20.3, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiZkFVX3lxTFBELVhFeFlqNWozQXltSXhHSEl2OFczc1ZnLS03MHBfYlJ5X0ZsUEt4M2FyZk1BdFZPOG5PVDlPaWRVejdoYU1WcXJpR1gwenBJM3RqTzV4dW81ckI3RUVKaXFUWnNNQQ?oc=5", "source_name": "TradingKey", "published_at": "2026-08-09T07:00:00+00:00", "tone_signals": ["Growth forecast"], "company_focus": 1.0, "freshness_pct": 6.0, "sentiment_pct": 59, "evidence_basis": "headline_only", "evidence_share": 0.9, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.008544, "influence_label": "Low", "event_confidence": 69, "company_focus_pct": 100, "evidence_strength": 35, "published_display": "09 Aug 2026 07:00", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.9"}, {"url": "https://news.stocktradersdaily.com/news_release/12/Understanding_Momentum_Shifts_in_BHVN_080926051002_1786266602.html", "tier": "direct", "title": "Understanding Momentum Shifts in (BHVN)", "topics": ["Financial Markets", "Life Sciences"], "summary": "This article analyzes Biohaven Ltd. (BHVN) stock, highlighting a potential shift where strong near-term sentiment might challenge persistent mid and long-term weakness. It identifies resistance testing and outlines three AI-generated trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014with specific entry, target, and stop-loss zones for different risk profiles. The analysis emphasizes risk-reward scenarios and multi-timeframe signal insights.", "age_days": 20.4, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.stocktradersdaily.com/news_release/12/Understanding_Momentum_Shifts_in_BHVN_080926051002_1786266602.html", "source_name": "Stock Traders Daily", "published_at": "2026-08-09T05:11:35+00:00", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 6e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "09 Aug 2026 05:11", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.marketscreener.com/news/biohaven-ltd-announces-appointment-of-john-yetimoglu-to-board-of-directors-effective-august-6-202-ce7f50dddb81f222", "tier": "direct", "title": "Biohaven Ltd. Announces Appointment of John Yetimoglu to Board of Directors, Effective August 6, 2026", "topics": ["Finance", "Life Sciences", "Technology"], "summary": "Biohaven Ltd. has announced the appointment of John Yetimoglu to its Board of Directors and as a member of the Nominating and Governance Committee, effective August 6, 2026. Mr. Yetimoglu, founder and CIO of Infinitum, brings expertise in semiconductors, videogaming, and AI application platforms. His appointment is expected to enhance the company's strategic oversight in leveraging AI and advanced computational methods for medical breakthroughs.", "age_days": 22.1, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.marketscreener.com/news/biohaven-ltd-announces-appointment-of-john-yetimoglu-to-board-of-directors-effective-august-6-202-ce7f50dddb81f222", "source_name": "www.marketscreener.com", "published_at": "2026-08-07T11:40:51+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 2.9e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "07 Aug 2026 11:40", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.morningstar.com/news/pr-newswire/20260806ne20330/biohaven-appoints-technology-investor-john-yetimoglu-to-board-of-directors", "tier": "direct", "title": "Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors", "topics": ["AI", "Appointments", "Biopharmaceuticals", "Drug Development", "Finance", "Life Sciences"], "summary": "Biohaven Ltd. (NYSE: BHVN) has appointed John Yetimoglu, founder and CIO of Infinitum and a board director at Groq, to its Board of Directors. Yetimoglu brings extensive experience in frontier AI and technology investing, which Biohaven anticipates will strengthen its strategic oversight as it integrates AI, machine learning, and advanced computational methods into drug discovery and development. This appointment highlights Biohaven's belief in the convergence of biology, data, and computation to drive future medical breakthroughs.", "age_days": 22.3, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.morningstar.com/news/pr-newswire/20260806ne20330/biohaven-appoints-technology-investor-john-yetimoglu-to-board-of-directors", "source_name": "Morningstar", "published_at": "2026-08-07T06:15:38+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 3.7e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "07 Aug 2026 06:15", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://ca.finance.yahoo.com/quote/BHVN", "tier": "direct", "title": "Biohaven Ltd. (BHVN) Stock Price, News, Quote & History", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "summary": "This Yahoo Finance page provides detailed stock information for Biohaven Ltd. (BHVN), including its current stock price, historical data, key events, and financial metrics. The company, a biopharmaceutical firm, focuses on treatments for immunology, neuroscience, and oncology, with several drug candidates in various clinical trial phases. The page also offers analyst insights, performance comparisons against the S&P 500, and a list of similar biotechnology companies.", "age_days": 22.7, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://ca.finance.yahoo.com/quote/BHVN", "source_name": "Yahoo! Finance Canada", "published_at": "2026-08-06T21:40:59+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 4.3, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.003541, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "06 Aug 2026 21:40", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/biohaven-bhvn-adds-ai-expertise-to-its-board-is-the-valuatio", "tier": "direct", "title": "Biohaven (BHVN) Adds AI Expertise To Its Board, Is The Valuation Gap Too Wide?", "topics": ["Earnings", "Financial Markets", "Life Sciences", "Technology"], "summary": "Biohaven (BHVN) recently appointed John Yetimoglu, an AI-focused investment leader, to its Board, signaling a stronger push into data-driven drug discovery. Despite recent stock volatility, a Discounted Cash Flow (DCF) model suggests Biohaven is significantly undervalued at $13.63, with a fair value estimate of $58.37 per share, driven by high future growth assumptions. However, its high Price-to-Book (P/B) ratio of 15.8x compared to industry averages and risks like limited cash runway and potential shareholder dilution present a mixed valuation picture.", "age_days": 22.8, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/biohaven-bhvn-adds-ai-expertise-to-its-board-is-the-valuatio", "source_name": "Simply Wall St", "published_at": "2026-08-06T19:40:00+00:00", "tone_signals": ["Dilution risk", "Positive valuation view"], "company_focus": 1.0, "freshness_pct": 4.3, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.005014, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "06 Aug 2026 19:40", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.citybiz.co/article/885111/biohaven-adds-technology-investor-john-yetimoglu-to-board-as-ai-strategy-advances", "tier": "direct", "title": "Biohaven Adds Technology Investor John Yetimoglu to Board as AI Strategy Advances", "topics": ["Life Sciences", "Technology"], "summary": "Biohaven Ltd. (NYSE: BHVN) has appointed technology investor John Yetimoglu to its Board of Directors to bolster its artificial intelligence and computational technologies strategy in drug discovery and development. Yetimoglu, founder of Infinitum and an early investor in Groq, brings extensive experience in emerging technologies and AI infrastructure to the biopharmaceutical company. This appointment reflects a growing trend in the life sciences industry to integrate AI expertise at the board level to accelerate innovation and decision-making.", "age_days": 23.1, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.citybiz.co/article/885111/biohaven-adds-technology-investor-john-yetimoglu-to-board-as-ai-strategy-advances", "source_name": "citybiz", "published_at": "2026-08-06T12:16:53+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 2.1e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "06 Aug 2026 12:16", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOa0w5ZmEyV0I4dUxEY1JZdkFJNm82Zy14Q1JUcHNzZWJsNHQzNi1IZWZGSmV3UnVFY01TTDBpS1FsWV83TzRzTEw0cWZlZmFfXzY0ejEwb2VvN0UxUG4xLTBRRENwaEZPN0Y0RlBPMlVPSWNJMkVMdV9IUUNjbmNGZElMYTl6bmVuQ2VZZ3c4c3NJb2tROHRLZVZ6OTFKTVgwVF9rbUVqVlhfSmIxdExDbDhJUHZhcFU?oc=5", "tier": "direct", "title": "Biohaven (BHVN) Expected to Release Quarterly Earnings on Monday", "topics": [], "summary": "", "age_days": 26.0, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOa0w5ZmEyV0I4dUxEY1JZdkFJNm82Zy14Q1JUcHNzZWJsNHQzNi1IZWZGSmV3UnVFY01TTDBpS1FsWV83TzRzTEw0cWZlZmFfXzY0ejEwb2VvN0UxUG4xLTBRRENwaEZPN0Y0RlBPMlVPSWNJMkVMdV9IUUNjbmNGZElMYTl6bmVuQ2VZZ3c4c3NJb2tROHRLZVZ6OTFKTVgwVF9rbUVqVlhfSmIxdExDbDhJUHZhcFU?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-03T13:30:02+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 2.7, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.002229, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "03 Aug 2026 13:30", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNSnVmQ3JuRnkxWTh6V0hMSDd2SF94eHRBSXJmQTFxOWlKTVRNbXgyZkMwNkVzRFQya3NxYkFjNDZHNVdSMHpiZnhfRi1URmxOVnRPd0N3R242WjFUbkNpQ0FnWjM5NHhfdlJTc0lnNkFOanRkZmtCY1YxTjdLbHlUUmM0S05WaXI2bmJwUjNibUxsX0FuSkJlNkREZkU5b01mUGhxc0lJbUlqa0h3RDM1ZEJ2clJwQTQ2QW9scG8zXzVyYU1OSHlJWElPQQ?oc=5", "tier": "direct", "title": "Defilade Capital Management L.P. Buys Shares of 315,944 Biohaven Ltd. $BHVN", "topics": [], "summary": "", "age_days": 26.3, "is_stale": false, "sentiment": "positive", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNSnVmQ3JuRnkxWTh6V0hMSDd2SF94eHRBSXJmQTFxOWlKTVRNbXgyZkMwNkVzRFQya3NxYkFjNDZHNVdSMHpiZnhfRi1URmxOVnRPd0N3R242WjFUbkNpQ0FnWjM5NHhfdlJTc0lnNkFOanRkZmtCY1YxTjdLbHlUUmM0S05WaXI2bmJwUjNibUxsX0FuSkJlNkREZkU5b01mUGhxc0lJbUlqa0h3RDM1ZEJ2clJwQTQ2QW9scG8zXzVyYU1OSHlJWElPQQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-03T07:00:00+00:00", "tone_signals": ["Institutional or insider buying"], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 58, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 1e-05, "influence_label": "Low", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 30, "published_display": "03 Aug 2026 07:00", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "<0.1"}, {"url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPdTJNd1ctbkdrdC1aNHR6YmxuaXFTdDA0Rm1GS3N5clY0dUROdjNEdWNqYjFkZFdFWDRTUGxfOU10Z0xwWkFrQ3JQX1B3SEI3ZmRHWlM0MWVlYXBGaml5NHdROEg2NzRtcFgyQk9ZeDMtYkJKWGIwaXJEYVduSzNKaVpTWmxOZmUtR0VRR2VYQVdWdGJ6MFBRWmstQ19rY1ZPUDJYcXNvS2VKY1NzajV4WGR5emVxYmR2MlE?oc=5", "tier": "direct", "title": "BHVN Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline Spending Intensifies - Growth Acceleration Report", "topics": [], "summary": "", "age_days": 27.3, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPdTJNd1ctbkdrdC1aNHR6YmxuaXFTdDA0Rm1GS3N5clY0dUROdjNEdWNqYjFkZFdFWDRTUGxfOU10Z0xwWkFrQ3JQX1B3SEI3ZmRHWlM0MWVlYXBGaml5NHdROEg2NzRtcFgyQk9ZeDMtYkJKWGIwaXJEYVduSzNKaVpTWmxOZmUtR0VRR2VYQVdWdGJ6MFBRWmstQ19rY1ZPUDJYcXNvS2VKY1NzajV4WGR5emVxYmR2MlE?oc=5", "source_name": "vinanet.vn", "published_at": "2026-08-02T07:00:00+00:00", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "freshness_pct": 2.3, "sentiment_pct": 43, "evidence_basis": "headline_only", "evidence_share": 0.3, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.002591, "influence_label": "Low", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 31, "published_display": "02 Aug 2026 07:00", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.3"}, {"url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPME1PMDUzYWFranR5eGwxTjZucGsyWGo1cXc0cDYyaDR4bmM5QXMtRTJybE1HQ1M1LW9iYWpNYkZjMmVXdnVzd0dGWHlQaTVJcWhqSXdZYnk3VEJ4ckptSXFjUnE0TTJ3bjZLcHJKUTNoMUx3WXJhQWpwUEJoSHB1dndkcDdmTzBKVmlxOUdQalFUUVd2aEZjWjlybTdvNmJuRGJHNkRxbGlQYThEenBiN2RaN29GaVpHZGRMR3BB?oc=5", "tier": "direct", "title": "Biohaven Ltd. $BHVN Shares Bought by Janus Henderson Group PLC", "topics": [], "summary": "", "age_days": 28.3, "is_stale": false, "sentiment": "positive", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPME1PMDUzYWFranR5eGwxTjZucGsyWGo1cXc0cDYyaDR4bmM5QXMtRTJybE1HQ1M1LW9iYWpNYkZjMmVXdnVzd0dGWHlQaTVJcWhqSXdZYnk3VEJ4ckptSXFjUnE0TTJ3bjZLcHJKUTNoMUx3WXJhQWpwUEJoSHB1dndkcDdmTzBKVmlxOUdQalFUUVd2aEZjWjlybTdvNmJuRGJHNkRxbGlQYThEenBiN2RaN29GaVpHZGRMR3BB?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-01T07:00:00+00:00", "tone_signals": ["Institutional or insider buying"], "company_focus": 1.0, "freshness_pct": 0.0, "sentiment_pct": 58, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 5e-06, "influence_label": "Low", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 30, "published_display": "01 Aug 2026 07:00", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "<0.1"}, {"url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPdE9sNmt5aDB4U2tPd3BzaGhMdDh1X2doNXZCUFFZcE1OREpBdHl2b1JFbExsTWdQeXJWVWNBMTlINlpDOXIxTkx2R0NkckZxWVoxeVJRZnZnX0Nyd0cwa3Z5OXVwTUIwZ19CYmZmUDd6ZWhOS0Y5Rkc0T1JEVERfU1VJVnNfMnBIbGNHWkprbW5KTGRvYWpiUEZqbVJ1OXh0UjFiMWlNVlNhQWM?oc=5", "tier": "direct", "title": "BHVN Q1 2026 Earnings: Wider-Than-Expected Loss Sends Shares Down 2.32% - Revenue Miss Report", "topics": [], "summary": "", "age_days": 28.3, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPdE9sNmt5aDB4U2tPd3BzaGhMdDh1X2doNXZCUFFZcE1OREpBdHl2b1JFbExsTWdQeXJWVWNBMTlINlpDOXIxTkx2R0NkckZxWVoxeVJRZnZnX0Nyd0cwa3Z5OXVwTUIwZ19CYmZmUDd6ZWhOS0Y5Rkc0T1JEVERfU1VJVnNfMnBIbGNHWkprbW5KTGRvYWpiUEZqbVJ1OXh0UjFiMWlNVlNhQWM?oc=5", "source_name": "vinanet.vn", "published_at": "2026-08-01T07:00:00+00:00", "tone_signals": ["Missed expectations"], "company_focus": 1.0, "freshness_pct": 2.0, "sentiment_pct": 21, "evidence_basis": "headline_only", "evidence_share": 0.5, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.004745, "influence_label": "Medium", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 55, "published_display": "01 Aug 2026 07:00", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.5"}, {"url": "https://m.investing.com/news/earnings/biohaven-pharma-earnings-on-deck-amid-epilepsy-trial-scrutiny-93CH-4828637?ampMode=1", "tier": "direct", "title": "Biohaven Pharma earnings on deck amid epilepsy trial scrutiny", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Biohaven Pharmaceutical Holding Co. is set to report second-quarter results, with analysts anticipating a narrower loss per share. Investors will be closely watching for updates on the company's cash runway and the timeline for pivotal Phase 2/3 epilepsy trial results for its experimental drug, opakalim, especially given growing skepticism about its differentiation from rivals. The company's recent restructuring efforts and upcoming clinical data are crucial for its valuation.", "age_days": 29.0, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://m.investing.com/news/earnings/biohaven-pharma-earnings-on-deck-amid-epilepsy-trial-scrutiny-93CH-4828637?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-31T14:09:20+00:00", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "freshness_pct": 1.8, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.002648, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "31 Jul 2026 14:09", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.moomoo.com/news/post/73833669/biohaven-insiders-added-us-33-1m-of-stock-to-their", "tier": "direct", "title": "Biohaven Insiders Added US$33.1m Of Stock To Their Holdings", "topics": ["Earnings", "Finance", "Life Sciences"], "summary": "This article discusses recent insider purchases at Biohaven Pharmaceutical Holding Company. Insiders bought US$33.1 million worth of stock, suggesting confidence in the company's future despite a recent share price decline. The purchases come after the company's acquisition of a migraine drug by Pfizer, which resulted in a significant special dividend for shareholders.", "age_days": 29.8, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.moomoo.com/news/post/73833669/biohaven-insiders-added-us-33-1m-of-stock-to-their", "source_name": "Moomoo", "published_at": "2026-07-30T20:11:24+00:00", "tone_signals": ["Institutional or insider buying"], "company_focus": 1.0, "freshness_pct": 1.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.001948, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "30 Jul 2026 20:11", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}], "by_tier": {"direct": [{"url": "https://finance.yahoo.com/m/16f3e772-1119-38de-adfd-c773a9f3693b/why-biohaven-stock-was.html", "tier": "direct", "title": "Why Biohaven Stock Was Rocking the Market This Week", "topics": [], "summary": "", "age_days": 1.3, "is_stale": false, "provider": "yfinance", "providers": ["yfinance"], "sentiment": "neutral", "story_key": "46d4f52bb8adf6855d11d9650a36ac809cec39816cee35fff129488ba979718f", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/m/16f3e772-1119-38de-adfd-c773a9f3693b/why-biohaven-stock-was.html", "source_name": "Motley Fool", "published_at": "2026-08-28T07:32:33+00:00", "source_names": ["Motley Fool"], "target_scope": "Why Biohaven Stock Was Rocking the Market This Week", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 64.2, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.026318, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["326030.KS", "BHVN", "BHVN.ARCHIVE", "NVDA"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "28 Aug 2026 07:32", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/m/dd6dbde2-0638-3f03-a583-89d9e229d6ad/sk-inks-%24795m-biohaven.html", "tier": "direct", "title": "SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race", "topics": [], "summary": "", "age_days": 2.0, "is_stale": false, "provider": "yfinance", "providers": ["yfinance"], "sentiment": "neutral", "story_key": "118dd6cfd0d5ef936c394165b035af1cf038f0eac7f5906aeb945679b11195b2", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/m/dd6dbde2-0638-3f03-a583-89d9e229d6ad/sk-inks-%24795m-biohaven.html", "source_name": "Pharmaceutical Technology", "published_at": "2026-08-27T14:40:43+00:00", "source_names": ["Pharmaceutical Technology"], "target_scope": "SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 82.2, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.060852, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "27 Aug 2026 14:40", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/healthcare/articles/bhvn-stock-soars-18-795m-134200709.html", "tier": "direct", "title": "BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program", "topics": ["Balance Sheet", "Biotech", "Earnings Per Share", "Epilepsy", "M A", "Partnership"], "summary": "Biohaven BHVN stock climbed 17.9% on Wednesday after the announcement of a strategic global licensing and collaboration agreement with South Korea-based SK Biopharmaceuticals. Under the deal, SK Biopharmaceuticals will receive exclusive worldwide rights to Biohaven's Kv7 ion channel platform, led by opakalim (BHV-7000), undergoing mid- to late-stage development for focal epilepsy. Under the terms, SK Biopharmaceuticals will provide upfront and milestone payments of up to $795 million related to the Kv7 platform. Biohaven will receive $400 million in cash consideration, including $350 million p", "age_days": 2.0, "is_stale": false, "provider": "yfinance", "providers": ["yfinance"], "sentiment": "positive", "story_key": "777ccc5eb61ea3ddb2bd54ffe919231a0394d66fa77306195f250895aae3dd52", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/bhvn-stock-soars-18-795m-134200709.html", "source_name": "Zacks", "published_at": "2026-08-27T13:42:00+00:00", "source_names": ["Zacks"], "target_scope": "BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program Biohaven BHVN stock climbed 17.9% on Wednesday after the announcement of a strategic global licensing and collaboration agreement with South Korea-based SK Biopharmaceuticals. Under the deal, SK Biopharmaceuticals will receive exclusive worldwide rights to Biohaven's Kv7 ion channel platform, led by opakalim (BHV-7000), undergoing mid- to late-stage development for focal epilepsy. Biohaven will receive $400 million in cash consideration, including $350 million p", "tone_signals": ["Large positive market reaction", "Positive market reaction"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 81.9, "sentiment_pct": 80, "evidence_basis": "archived_article", "evidence_share": 21.2, "score_included": true, "duplicate_count": 3, "durable_archive": false, "evidence_weight": 0.204543, "influence_label": "High", "provider_symbol": "BHVN.US", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.791, "provider_symbols": ["326030.KS", "ACIU.US", "AMRX.US", "BHVN", "BHVN.ARCHIVE", "BHVN.US", "PGEN.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 72, "published_display": "27 Aug 2026 13:42", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "21.2", "target_provider_symbol": "BHVN", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/markets/stocks/articles/biohaven-shares-rise-epilepsy-drug-182910055.html", "tier": "direct", "title": "Update: Biohaven Shares Rise After Epilepsy Drug Licensing Deal", "topics": [], "summary": "", "age_days": 2.8, "is_stale": false, "provider": "yfinance", "providers": ["yfinance"], "sentiment": "neutral", "story_key": "1ed0706dec886856065b832be4f1d353b8b59c5cea21140142327ad9c175716d", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/markets/stocks/articles/biohaven-shares-rise-epilepsy-drug-182910055.html", "source_name": "MT Newswires", "published_at": "2026-08-26T18:29:10+00:00", "source_names": ["MT Newswires"], "target_scope": "Update: Biohaven Shares Rise After Epilepsy Drug Licensing Deal", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 75.6, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.042923, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["326030.KS", "BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "26 Aug 2026 18:29", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/m/3d441be9-13a0-30c9-8fdb-a3c36bebaa34/biohaven-shares-climb-7%25.html", "tier": "direct", "title": "Biohaven shares climb 7% after signing major SK Biopharmaceuticals licensing deal", "topics": [], "summary": "", "age_days": 3.1, "is_stale": false, "provider": "yfinance", "providers": ["yfinance"], "sentiment": "positive", "story_key": "d7157af20f87cdc18401be903b87c2e0d3a0d37b639101725f7d8ed8d0b7f24e", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/m/3d441be9-13a0-30c9-8fdb-a3c36bebaa34/biohaven-shares-climb-7%25.html", "source_name": "InvestorsHub", "published_at": "2026-08-26T12:28:24+00:00", "source_names": ["InvestorsHub"], "target_scope": "Biohaven shares climb 7% after signing major SK Biopharmaceuticals licensing deal", "tone_signals": ["Positive market reaction", "Large positive market reaction"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 73.8, "sentiment_pct": 67, "evidence_basis": "headline_only", "evidence_share": 10.7, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.102751, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.652, "provider_symbols": ["326030.KS", "BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 54, "published_display": "26 Aug 2026 12:28", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "10.7", "target_provider_symbol": "BHVN", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/m/1e91c2b4-76e0-3830-b47e-a53a4ff0d9f6/biohaven-trades-cash-for.html", "tier": "direct", "title": "Biohaven trades cash for \u2018upside\u2019 with $795M epilepsy drug deal", "topics": [], "summary": "", "age_days": 3.1, "is_stale": false, "provider": "yfinance", "providers": ["yfinance"], "sentiment": "positive", "story_key": "5a7e0a4b622bf4c465b94c253bc3813877bc532c005f071c3491caf562091a44", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/m/1e91c2b4-76e0-3830-b47e-a53a4ff0d9f6/biohaven-trades-cash-for.html", "source_name": "BioPharma Dive", "published_at": "2026-08-26T11:17:41+00:00", "source_names": ["BioPharma Dive"], "target_scope": "Biohaven trades cash for \u2018upside\u2019 with $795M epilepsy drug deal", "tone_signals": ["Positive financial language"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 73.4, "sentiment_pct": 57, "evidence_basis": "headline_only", "evidence_share": 6.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.057776, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.461, "provider_symbols": ["326030.KS", "BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 42, "published_display": "26 Aug 2026 11:17", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "6", "target_provider_symbol": "BHVN", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/healthcare/articles/biohaven-sk-biopharmaceuticals-enter-strategic-060100876.html", "tier": "direct", "title": "Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy", "topics": ["Balance Sheet", "Biopharmaceuticals", "Epilepsy", "Licensing Agreement"], "summary": "SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim. Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026. It is designed to offer an easy-to-use, once-daily oral treatment without the need for titration and a low incidence of burdens", "age_days": 3.3, "is_stale": false, "provider": "eodhd", "providers": ["eodhd"], "sentiment": "neutral", "story_key": "42dfe49ac46aa9545630f81a60e5d2f6e66a3a68c4b49416a844c11685aa385b", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/biohaven-sk-biopharmaceuticals-enter-strategic-060100876.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-26T06:01:00+00:00", "source_names": ["finance.yahoo.com"], "target_scope": "Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026.", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 62.9, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.036376, "influence_label": "None", "provider_symbol": "BHVN.US", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["326030.KS", "BHVN.ARCHIVE", "BHVN.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "26 Aug 2026 06:01", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN.US", "provider_directional_mass": 0.12}, {"url": "https://news.google.com/rss/articles/CBMingJBVV95cUxOUGZHYWxNaGFacDdSUXNxQTQ2a0l4cTRjdm1KNURaNlk2V3RXaHBnNlIweUtRaGsta242THBqaHBpbjgtd2E3SmJYWi1FcFBxaW4wSGg5NFpCa2VpXzN1WnVWNFJudFBIcGJRTmNVbUl5elFzbnFWdVU2S2dDNFVBNlJyRFI1NTc5bHhLWlRCM25zVm1hUUhYbVotbDNCWWQ1RmxJbGU2Z2x6WnNVcEdNYUJJaElyRkpNRUZobEJMZklvVFFJU1ZpR1cwMm1KRjFkd1dieGx0UWFMMW15WmQ3d2NtVlgtOU13V1g5UC1fVkJkbFQ5czZDTEp5SDUtMzFIanRyYjd0OFZHSWt2WTBGR2JwUGNwYTFHT080cW9n?oc=5", "tier": "direct", "title": "Biohaven (BHVN) Financial Update: The Available Earnings Metric Delivers a Miss for This Review; Post-Earnings: Shares Move 5.12% Higher in the Latest Session - Pre-Earnings Drift", "topics": [], "summary": "", "age_days": 3.4, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "negative", "story_key": "31465ffc062b340ddefeec578d2fe41655db53d31f3a4697546436d5e45d74dd", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMingJBVV95cUxOUGZHYWxNaGFacDdSUXNxQTQ2a0l4cTRjdm1KNURaNlk2V3RXaHBnNlIweUtRaGsta242THBqaHBpbjgtd2E3SmJYWi1FcFBxaW4wSGg5NFpCa2VpXzN1WnVWNFJudFBIcGJRTmNVbUl5elFzbnFWdVU2S2dDNFVBNlJyRFI1NTc5bHhLWlRCM25zVm1hUUhYbVotbDNCWWQ1RmxJbGU2Z2x6WnNVcEdNYUJJaElyRkpNRUZobEJMZklvVFFJU1ZpR1cwMm1KRjFkd1dieGx0UWFMMW15WmQ3d2NtVlgtOU13V1g5UC1fVkJkbFQ5czZDTEp5SDUtMzFIanRyYjd0OFZHSWt2WTBGR2JwUGNwYTFHT080cW9n?oc=5", "source_name": "vinanet.vn", "published_at": "2026-08-26T04:48:41+00:00", "source_names": ["vinanet.vn"], "target_scope": "Biohaven (BHVN) Financial Update: The Available Earnings Metric Delivers a Miss for This Review", "tone_signals": ["Missed expectations"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 62.5, "sentiment_pct": 25, "evidence_basis": "headline_only", "evidence_share": 13.9, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.133547, "influence_label": "High", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.59, "provider_symbols": ["BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 64, "published_display": "26 Aug 2026 04:48", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "13.9", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://ca.investing.com/news/stock-market-news/biohaven-yale-win-4m-judgment-in-trade-secret-case-93CH-4816327", "tier": "direct", "title": "Biohaven, Yale win $4M judgment in trade secret case By Investing.com", "topics": ["Finance", "Life Sciences"], "summary": "Biohaven Ltd. and Yale University have been awarded a combined $4 million judgment in a trade secret misappropriation and breach of contract lawsuit against Avilar Therapeutics, Inc. and RA Capital Management GP, LLC. The judgment follows a jury verdict which found that RA Capital and Avilar willfully and maliciously misappropriated Yale's MODA targeted protein degradation platform trade secret and that RA Capital breached a 2019 confidentiality agreement with Yale. Yale received $2 million for the breach of contract and $1 million each from both Biohaven and Yale for trade secret misappropriation.", "age_days": 3.7, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "7b65667da64abc190d51d683424be4c7c601ec5c7734cad75a27dd5281d7c834", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://ca.investing.com/news/stock-market-news/biohaven-yale-win-4m-judgment-in-trade-secret-case-93CH-4816327", "source_name": "Investing.com Canada", "published_at": "2026-08-25T20:44:51+00:00", "source_names": ["Investing.com Canada"], "target_scope": "Biohaven, Yale win $4M judgment in trade secret case By Investing.com Biohaven Ltd. Yale received $2 million for the breach of contract and $1 million each from both Biohaven and Yale for trade secret misappropriation.", "tone_signals": ["Legal or regulatory risk"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 69.1, "sentiment_pct": 45, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.123147, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 53, "model_confidence": 0.531, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "25 Aug 2026 20:44", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.prnewswire.com/news-releases/federal-court-enters-judgment-confirming-ra-capital-and-avilar-therapeutics-willfully-and-maliciously-misappropriated-trade-secret-developed-at-yale-formalizing-4-million-award-to-biohaven-and-yale-university-302859834.html", "tier": "direct", "title": "Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University", "topics": ["Finance", "Life Sciences"], "summary": "A U.S. District Court in Delaware has formalized a $4 million award to Biohaven Ltd. and Yale University, ruling that RA Capital Management GP, LLC and Avilar Therapeutics, Inc. willfully and maliciously misappropriated a trade secret related to Yale's \"MODA\" protein degradation platform. The judgment confirms a jury's verdict, with $2 million awarded to Yale for RA Capital's breach of contract and $1 million each to Yale and Biohaven for trade secret misappropriation. Biohaven had licensed the MODA platform from Yale and pursued litigation after RA Capital allegedly used confidential information to establish a competing company, Avilar, rather than partnering with Yale.", "age_days": 3.7, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "f62ac7c0aa5e81eda47b3e49a3aa6acf2e9ec345004dcf8371debd16ff32ec08", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "press_release", "source_link": "https://www.prnewswire.com/news-releases/federal-court-enters-judgment-confirming-ra-capital-and-avilar-therapeutics-willfully-and-maliciously-misappropriated-trade-secret-developed-at-yale-formalizing-4-million-award-to-biohaven-and-yale-university-302859834.html", "source_name": "PR Newswire", "published_at": "2026-08-25T20:44:51", "source_names": ["PR Newswire"], "target_scope": "Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University District Court in Delaware has formalized a $4 million award to Biohaven Ltd. The judgment confirms a jury's verdict, with $2 million awarded to Yale for RA Capital's breach of contract and $1 million each to Yale and Biohaven for trade secret misappropriation. Biohaven had licensed the MODA platform from Yale and pursued litigation after RA Capital allegedly used confidential information to establish a competing company, Avilar, rather than partnering with Yale.", "tone_signals": ["Contract or approval won"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 69.1, "sentiment_pct": 55, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.105023, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.533, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "25 Aug 2026 20:44", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN", "provider_directional_mass": 0.472}, {"url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxOeVVMVU5UaGVvb3pnWWpMVk81S0ZaUU1BV19ISFdvNzFoUVZlSFhDbVkzTC0xbS1OSi1SQXY4Vi1PeXBkSHRiZ3IyU0RaMWJraVJ1ajRjTTZwakk1NkYwcWpDeUdiZHpMTGo0c2FhcEEwNFhJU0FYTUpna0xIcHJ4ZHU4RE9Pd0ZVWlpsNEs0SC1JZ25TbVBPVFlHamlIczU4dFNXSURhUWZRMDduMlFWd0VHUEhnR3hxa2RDZExLRWU4MmJHbERnVUh1cTVBSlZLR2xXT21BSUJsdk1QcFVHSVRpV0ZXWHEtanZwczhiMHhKS19YU0k4NFZmc3RnSEc0a2RUc3NzM19lZlg1RDRVNU9WYlNEdlc3U0NwMTNzWHcyLS1kdDljNXl3VnM?oc=5", "tier": "direct", "title": "BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout", "topics": [], "summary": "", "age_days": 4.0, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "671977897eb6cbe29380a6458c1e5744d0ab1da9d0b9ea4bc7417abd8610e913", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMirAJBVV95cUxOeVVMVU5UaGVvb3pnWWpMVk81S0ZaUU1BV19ISFdvNzFoUVZlSFhDbVkzTC0xbS1OSi1SQXY4Vi1PeXBkSHRiZ3IyU0RaMWJraVJ1ajRjTTZwakk1NkYwcWpDeUdiZHpMTGo0c2FhcEEwNFhJU0FYTUpna0xIcHJ4ZHU4RE9Pd0ZVWlpsNEs0SC1JZ25TbVBPVFlHamlIczU4dFNXSURhUWZRMDduMlFWd0VHUEhnR3hxa2RDZExLRWU4MmJHbERnVUh1cTVBSlZLR2xXT21BSUJsdk1QcFVHSVRpV0ZXWHEtanZwczhiMHhKS19YU0k4NFZmc3RnSEc0a2RUc3NzM19lZlg1RDRVNU9WYlNEdlc3U0NwMTNzWHcyLS1kdDljNXl3VnM?oc=5", "source_name": "Stocktwits", "published_at": "2026-08-25T13:30:03+00:00", "source_names": ["Stocktwits"], "target_scope": "BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 24.7, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.010141, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["326030.KS", "BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "25 Aug 2026 13:30", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxQQmN1eFVJUGlhX0NRQW5uX0ZUZUczNWtFeTl2SFFaWkFDRGs1NHg4UVVNdVBCa19zQzBfQ0JjSEZGc3hqMFVjVFpjbmh3cG1hTUxWQ3BSYmNMTktGWnhJaTA4RkZZb29rbXNpeV9jUkZCaUk5dWg4YWF5UG5UUi0xS0x1djRzQVRWdl9iRDlwQ3ZtQ3NqaVJZQWlUVXEydE1qejRkUVh4NnVPNkdrM21lYTB3TXl3YV9iWFpVa3kybXUtRFI1emI2NzJxOGJMd085a1pLMFpZN3RmVDBzSEo3QkUzRjlTam5YalpNMWg1VzFZeVVvbUtDZkhIWldQZmlEcFFqdHhRQ2xkQQ?oc=5", "tier": "direct", "title": "Biohaven (BHVN) Q2 2026 Earnings: The Bottom-Line Figure Trails Its Comparison on the Day; Share Response", "topics": [], "summary": "", "age_days": 5.1, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "e142c26a9edb35100be271a5963f411fb83dae7a8606dae32f150449d6b2c8ce", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiigJBVV95cUxQQmN1eFVJUGlhX0NRQW5uX0ZUZUczNWtFeTl2SFFaWkFDRGs1NHg4UVVNdVBCa19zQzBfQ0JjSEZGc3hqMFVjVFpjbmh3cG1hTUxWQ3BSYmNMTktGWnhJaTA4RkZZb29rbXNpeV9jUkZCaUk5dWg4YWF5UG5UUi0xS0x1djRzQVRWdl9iRDlwQ3ZtQ3NqaVJZQWlUVXEydE1qejRkUVh4NnVPNkdrM21lYTB3TXl3YV9iWFpVa3kybXUtRFI1emI2NzJxOGJMd085a1pLMFpZN3RmVDBzSEo3QkUzRjlTam5YalpNMWg1VzFZeVVvbUtDZkhIWldQZmlEcFFqdHhRQ2xkQQ?oc=5", "source_name": "vinanet.vn", "published_at": "2026-08-24T12:32:11+00:00", "source_names": ["vinanet.vn"], "target_scope": "Biohaven (BHVN) Q2 2026 Earnings: The Bottom-Line Figure Trails Its Comparison on the Day", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 49.5, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.040733, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "24 Aug 2026 12:32", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.sahmcapital.com/news/content/is-biohaven-bhvn-undervalued-following-its-latest-earnings-loss-improvement-2026-08-23", "tier": "direct", "title": "Is Biohaven (BHVN) Undervalued Following Its Latest Earnings Loss Improvement?", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "summary": "Biohaven (BHVN) reported improved Q2 2026 earnings, reducing its net loss to US$137.31 million. While the stock's price-to-book ratio of 171.2x suggests overvaluation compared to industry averages, a Discounted Cash Flow (DCF) model from Simply Wall St indicates the shares might be significantly undervalued at $13.85, estimating a future cash flow value of $53.83 per share. The article highlights the conflicting valuation perspectives, urging investors to consider both the risks of a loss-making biotech and the potential of its pipeline.", "age_days": 5.2, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "positive", "story_key": "e3160ee14cd9fff33549fb54facaf3a7038d0a81ffbb0e21a30930d93da54a5d", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.sahmcapital.com/news/content/is-biohaven-bhvn-undervalued-following-its-latest-earnings-loss-improvement-2026-08-23", "source_name": "Sahm", "published_at": "2026-08-24T09:16:31+00:00", "source_names": ["Sahm"], "target_scope": "Is Biohaven (BHVN) Undervalued Following Its Latest Earnings Loss Improvement? Biohaven (BHVN) reported improved Q2 2026 earnings, reducing its net loss to US$137.31 million.", "tone_signals": ["Positive valuation view", "Improving financial comparison"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 48.6, "sentiment_pct": 57, "evidence_basis": "archived_article", "evidence_share": 10.2, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.098656, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 53, "model_confidence": 0.702, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 43, "published_display": "24 Aug 2026 09:16", "direction_included": true, "sentiment_conflict": 0.469, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "10.2", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/why-biohaven-bhvn-is-down-91-after-reporting-narrower-q2-and", "tier": "direct", "title": "Why Biohaven (BHVN) Is Down 9.1% After Reporting Narrower Q2 and H1 Net Losses", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Biohaven Ltd. reported narrower net losses for Q2 and H1 2026, with Q2 losses at US$137.31 million and H1 losses at US$267.84 million. Despite this, the company's shares dropped 9.1%, and concerns remain regarding its cash burn, reliance on future capital raises, and whether its significant pipeline can justify current spending. Investors are advised to consider various perspectives and the company's financial health before making investment decisions.", "age_days": 7.0, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "negative", "story_key": "d3af7cead7d4b937069f79b75ebbd721f91540144433025406c3eb2a8aedbd3b", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/why-biohaven-bhvn-is-down-91-after-reporting-narrower-q2-and", "source_name": "Simply Wall Street", "published_at": "2026-08-22T13:13:56+00:00", "source_names": ["Simply Wall Street"], "target_scope": "Why Biohaven (BHVN) Is Down 9.1% After Reporting Narrower Q2 and H1 Net Losses Biohaven Ltd.", "tone_signals": ["Negative market reaction", "Large negative market reaction"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 37.7, "sentiment_pct": 34, "evidence_basis": "archived_article", "evidence_share": 9.5, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.091871, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 53, "model_confidence": 0.686, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 50, "published_display": "22 Aug 2026 13:13", "direction_included": true, "sentiment_conflict": 0.132, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "9.5", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOLVRZeFg4c3ZBZ0RtRkxsaUVYQm4tQ2JzME81NnQ0bWFxckJISE40YW1FSXBjWS0zYVoxdTA4TmVFbDNWek5ZcFdQaS01V3BpaDd3RFhaTXREbWQweHI3d0R4czNyUlJ5dW16N0VlLVNsMGdkRnFkTE9SWndfcDh1Y1dndjR3SkdRM0VZMU9iMklrLWpqaVBaWnJnUlcxUWc?oc=5", "tier": "direct", "title": "Price to earnings forward of Biohaven Ltd. \u2013 NYSE:BHVN", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "This article provides financial information for Biohaven Ltd. (NYSE: BHVN), specifically focusing on its forward price-to-earnings ratio. The content appears to be a page from a financial data platform, displaying the company's ticker, exchange, and a placeholder for the \"Price to earnings forward\" value.", "age_days": 7.5, "is_stale": false, "provider": "google_news", "providers": ["alphavantage", "google_news"], "sentiment": "neutral", "story_key": "d74f8e798aa5d629a2ca87844d1844e0cf159bd8865a72aa08ebca4fbb82cb3f", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOLVRZeFg4c3ZBZ0RtRkxsaUVYQm4tQ2JzME81NnQ0bWFxckJISE40YW1FSXBjWS0zYVoxdTA4TmVFbDNWek5ZcFdQaS01V3BpaDd3RFhaTXREbWQweHI3d0R4czNyUlJ5dW16N0VlLVNsMGdkRnFkTE9SWndfcDh1Y1dndjR3SkdRM0VZMU9iMklrLWpqaVBaWnJnUlcxUWc?oc=5", "source_name": "TradingView", "published_at": "2026-08-22T01:37:32+00:00", "source_names": ["TradingView"], "target_scope": "Price to earnings forward of Biohaven Ltd. \u2013 NYSE:BHVN This article provides financial information for Biohaven Ltd. (NYSE: BHVN), specifically focusing on its forward price-to-earnings ratio.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 35.2, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.033821, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "22 Aug 2026 01:37", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPR1BZQnByN2N5dFNuaWZsbnFWNlBHTUd3MXNrTHh3S2s4TWYxbnpZeFZiT3RFbFhISndtdDBhMkd6U2hkLWxtVXYxa19lQ0cxNTlVaDJDcXFtdHZpTVc1Y1A5bU9ObVhsLVZCSzBYajVXTkE5aVlQX2xkUnFOQVZlMEZManFaVnpwXy1zMUI0RURCbjg2UWtLWVFTODdlWkI3MUV3b0lqbGk3UXhJeXc?oc=5", "tier": "direct", "title": "HC Wainwright Decreases Earnings Estimates for Biohaven", "topics": [], "summary": "", "age_days": 8.1, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "69751c9785a5e6936b14f8ef9395a6a9d794b81515c76622d393df33c2f4874f", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPR1BZQnByN2N5dFNuaWZsbnFWNlBHTUd3MXNrTHh3S2s4TWYxbnpZeFZiT3RFbFhISndtdDBhMkd6U2hkLWxtVXYxa19lQ0cxNTlVaDJDcXFtdHZpTVc1Y1A5bU9ObVhsLVZCSzBYajVXTkE5aVlQX2xkUnFOQVZlMEZManFaVnpwXy1zMUI0RURCbjg2UWtLWVFTODdlWkI3MUV3b0lqbGk3UXhJeXc?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-21T12:45:30+00:00", "source_names": ["MarketBeat"], "target_scope": "", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": false, "freshness_pct": 32.7, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.031398, "influence_label": "None", "provider_symbol": "", "relevance_score": null, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": [], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "21 Aug 2026 12:45", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNSko4T1N6VU5mZFppMVNMbnRGdXUtZ0NPaU85N0ZyYWpOZEVUTW1EemtNdkg1bng1RHdNN01PMkEtMFk0a0c4anNSYzJ1OThHQmhOdWJCYmU3QjdHTktWM296QW8xY0MzbzM1V1pQRHlnTmx5SUZqcmFVTHd3UUJuWWx1NDhWWkgwbDg1WW9GcmsyUXBUb2FLNXBLMGVGeEJUbDJBcHZleG5QaXliWThySWNLcG9ObWhCOHBiX283VjExLTVrNWM5ZUE2RmFEUQ?oc=5", "tier": "direct", "title": "Biohaven Ltd. (NYSE:BHVN) Receives Consensus Rating of \"Moderate Buy\" from Brokerages", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "summary": "Biohaven Ltd. (NYSE:BHVN) has received a \"Moderate Buy\" consensus rating from seventeen research firms, with an average 12-month price target of $21.75. The company's shares opened at $13.59, and it recently reported a quarterly EPS of negative $0.91, missing the consensus estimate. Institutional investors hold 88.78% of the stock, and analysts anticipate a full-year loss of approximately $3.11 per share.", "age_days": 10.3, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "c7d31b583477382cfe6d56bdeaaa012688686980515ed1b06a4d5bc830661aa0", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNSko4T1N6VU5mZFppMVNMbnRGdXUtZ0NPaU85N0ZyYWpOZEVUTW1EemtNdkg1bng1RHdNN01PMkEtMFk0a0c4anNSYzJ1OThHQmhOdWJCYmU3QjdHTktWM296QW8xY0MzbzM1V1pQRHlnTmx5SUZqcmFVTHd3UUJuWWx1NDhWWkgwbDg1WW9GcmsyUXBUb2FLNXBLMGVGeEJUbDJBcHZleG5QaXliWThySWNLcG9ObWhCOHBiX283VjExLTVrNWM5ZUE2RmFEUQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-19T06:32:50+00:00", "source_names": ["MarketBeat"], "target_scope": "Biohaven Ltd. (NYSE:BHVN) Receives Consensus Rating of \"Moderate Buy\" from Brokerages Biohaven Ltd. (NYSE:BHVN) has received a \"Moderate Buy\" consensus rating from seventeen research firms, with an average 12-month price target of $21.75.", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 9.2, "sentiment_pct": 46, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.009332, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "google_news", "event_confidence": 61, "model_confidence": 0.47, "provider_symbols": ["BAC", "BHVN", "BHVN.ARCHIVE", "PNC", "RF", "SCHW"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "19 Aug 2026 06:32", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.marketbeat.com/instant-alerts/filing-biohaven-ltd-bhvn-shares-bought-by-quantinno-capital-management-lp-2026-08-16", "tier": "direct", "title": "Biohaven Ltd. $BHVN Shares Bought by Quantinno Capital Management LP", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "summary": "Quantinno Capital Management LP significantly increased its stake in Biohaven Ltd. (BHVN) by 190% in the first quarter, bringing its total to 121,554 shares. Several other institutional investors also expanded their positions, contributing to the high institutional ownership of 88.78%. Despite a reported quarterly loss of $0.91 per share, analysts maintain a \"Moderate Buy\" rating with a consensus price target of $21.75, considerably higher than the stock's recent trading price.", "age_days": 13.1, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "positive", "story_key": "968dcf346f5d7c9323be724226a7153f9ba3663748c9259022c0b8e10ccec5cb", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/instant-alerts/filing-biohaven-ltd-bhvn-shares-bought-by-quantinno-capital-management-lp-2026-08-16", "source_name": "MarketBeat", "published_at": "2026-08-16T12:10:10+00:00", "source_names": ["MarketBeat"], "target_scope": "Biohaven Ltd. $BHVN Shares Bought by Quantinno Capital Management LP Quantinno Capital Management LP significantly increased its stake in Biohaven Ltd. (BHVN) by 190% in the first quarter, bringing its total to 121,554 shares.", "tone_signals": ["Institutional or insider buying"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 16.3, "sentiment_pct": 58, "evidence_basis": "archived_article", "evidence_share": 3.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.029284, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 61, "model_confidence": 0.607, "provider_symbols": ["AMAT", "BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 36, "published_display": "16 Aug 2026 12:10", "direction_included": true, "sentiment_conflict": 0.244, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "3", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.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?oc=5", "tier": "direct", "title": "Biohaven (BHVN) Could Be 73% Undervalued As Regeneron Deal Expands", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Biohaven (BHVN) is gaining attention after expanding its oncology collaboration with Regeneron Pharmaceuticals. Despite a recent slight easing in share price, the stock shows strong 90-day returns, contrasting with weaker long-term performance. A discounted cash flow (DCF) model by Simply Wall St suggests Biohaven could be 73% undervalued, estimating a fair value of $54.53 against its current trading price of $14.64, although its high P/B ratio indicates significant valuation risk.", "age_days": 13.8, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "positive", "story_key": "d3a5b1cea7d6c357f87907783359c80641d881dee17f23ed216fd42b9147cf55", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-08-15T18:40:36+00:00", "source_names": ["Simply Wall Street", "simplywall.st"], "target_scope": "Biohaven (BHVN) Could Be 73% Undervalued As Regeneron Deal Expands Biohaven (BHVN) is gaining attention after expanding its oncology collaboration with Regeneron Pharmaceuticals. A discounted cash flow (DCF) model by Simply Wall St suggests Biohaven could be 73% undervalued, estimating a fair value of $54.53 against its current trading price of $14.64, although its high P/B ratio indicates significant valuation risk.", "tone_signals": ["Positive valuation view"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 14.7, "sentiment_pct": 70, "evidence_basis": "archived_article", "evidence_share": 4.1, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.039094, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "google_news", "event_confidence": 53, "model_confidence": 0.692, "provider_symbols": ["BHVN", "BHVN.ARCHIVE", "REGN"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 49, "published_display": "15 Aug 2026 18:40", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "4.1", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/is-biohavens-narrowing-losses-and-ai-board-hire-altering-the", "tier": "direct", "title": "Is Biohaven\u2019s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)?", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences", "Technology"], "summary": "Biohaven Ltd. reported narrowing losses in Q2 2026, with a net loss of US$137.31 million, and appointed AI-focused investor John Yetimoglu to its Board. Despite these developments, the company still faces significant financial risk due to zero revenue, heavy ongoing losses, and a short cash runway, with investors needing to consider future funding and potential dilution. The article suggests that while the AI appointment aligns with Biohaven's data-driven R&D, it doesn't immediately alter the key value drivers of its epilepsy and MoDE degrader programs.", "age_days": 14.6, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "negative", "story_key": "20061d160be32679b6a951ffbe1e89abe480bc3dfa8eb95f7a2b3224b2626634", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/is-biohavens-narrowing-losses-and-ai-board-hire-altering-the", "source_name": "Simply Wall Street", "published_at": "2026-08-14T23:10:10+00:00", "source_names": ["Simply Wall Street"], "target_scope": "Is Biohaven\u2019s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)? Biohaven Ltd. The article suggests that while the AI appointment aligns with Biohaven's data-driven R&D, it doesn't immediately alter the key value drivers of its epilepsy and MoDE degrader programs.", "tone_signals": ["Dilution risk"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 13.2, "sentiment_pct": 33, "evidence_basis": "archived_article", "evidence_share": 3.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.029046, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 53, "model_confidence": 0.612, "provider_symbols": ["BHVN", "BHVN.ARCHIVE", "BIIB", "VRTX"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 45, "published_display": "14 Aug 2026 23:10", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "3", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://finance.yahoo.com/healthcare/articles/biohaven-bhvn-latest-regeneron-pharmaceuticals-222352923.html", "tier": "direct", "title": "Is Biohaven (BHVN)\u2019s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?", "topics": ["Biotech", "Clinical Trials", "Earnings", "Net Income", "Pharma", "Price Target"], "summary": "Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron's cemiplimab (Libtayo) in patients with solid tumors. BHV-1530's novel topoisomerase I (TopoIx) payload generates immunogenic cell death and triggers antitumor immune responses, creating a compelling rationale when paired with checkpoint inhibition. Building on an earlier agreement for BHV-1510, a TROP2-d", "age_days": 14.7, "is_stale": false, "provider": "eodhd", "providers": ["eodhd"], "sentiment": "neutral", "story_key": "eb2e36e64745012e02e0fbd3bd50cbb8308fa479808ddeb85f145c184010d9fc", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "aggregator", "source_link": "https://finance.yahoo.com/healthcare/articles/biohaven-bhvn-latest-regeneron-pharmaceuticals-222352923.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-14T22:23:52+00:00", "source_names": ["finance.yahoo.com"], "target_scope": "Is Biohaven (BHVN)\u2019s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline? Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron's cemiplimab (Libtayo) in patients with solid tumors.", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 13.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.007576, "influence_label": "None", "provider_symbol": "BHVN.US", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["BHVN.ARCHIVE", "BHVN.US", "GILD.US", "MGNX.US", "REGN.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "14 Aug 2026 22:23", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN.US", "provider_directional_mass": 0.142}, {"url": "https://www.stocktitan.net/sec-filings/BHVN/schedule-13g-biohaven-ltd-passive-investment-disclosure-5-c85f0e31a822.html", "tier": "direct", "title": "Woodline Partners (BHVN) discloses 5.1% beneficial stake in Biohaven", "topics": ["Financial Markets", "Life Sciences"], "summary": "Woodline Partners LP has reported a beneficial ownership of 5.1% in Biohaven Ltd., amounting to 7,660,280 Common Shares. This ownership grants Woodline Partners sole voting and dispositive power over these shares, which are held through Woodline Master Fund LP and Woodline Spire Master Fund LP. The stake is based on Biohaven's 150,560,990 Common Shares outstanding as of April 30, 2026.", "age_days": 15.0, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "aecc09ffbae4c7a1ac7a1dd4e5fd4032d6fa32af43baedbdd39ee6f764f7be4c", "event_type": "deals", "tier_label": "Direct company coverage", "event_label": "Deals and strategy", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/BHVN/schedule-13g-biohaven-ltd-passive-investment-disclosure-5-c85f0e31a822.html", "source_name": "Stock Titan", "published_at": "2026-08-14T15:12:26+00:00", "source_names": ["Stock Titan"], "target_scope": "Woodline Partners (BHVN) discloses 5.1% beneficial stake in Biohaven Woodline Partners LP has reported a beneficial ownership of 5.1% in Biohaven Ltd., amounting to 7,660,280 Common Shares. The stake is based on Biohaven's 150,560,990 Common Shares outstanding as of April 30, 2026.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 22.7, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.019642, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "14 Aug 2026 15:12", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-acquires-new-position-in-biohaven-ltd-bhvn-2026-08-14", "tier": "direct", "title": "Renaissance Technologies LLC Acquires New Position in Biohaven Ltd. $BHVN", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Renaissance Technologies LLC has acquired a new position in Biohaven Ltd. (NYSE:BHVN), purchasing 160,952 shares valued at approximately $1.36 million. This move comes as institutional investors collectively own 88.78% of Biohaven, with several major funds significantly increasing their stakes. Despite missing quarterly EPS expectations, analysts maintain a \"Moderate Buy\" rating with an average price target of $21.75 for Biohaven.", "age_days": 15.1, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "positive", "story_key": "b32397aa690f5b0bd1d49109e67e51ead9bc8646da2d423d576b1e9dfad70042", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-acquires-new-position-in-biohaven-ltd-bhvn-2026-08-14", "source_name": "MarketBeat", "published_at": "2026-08-14T11:12:26", "source_names": ["MarketBeat"], "target_scope": "Renaissance Technologies LLC Acquires New Position in Biohaven Ltd. $BHVN Renaissance Technologies LLC has acquired a new position in Biohaven Ltd. (NYSE:BHVN), purchasing 160,952 shares valued at approximately $1.36 million. This move comes as institutional investors collectively own 88.78% of Biohaven, with several major funds significantly increasing their stakes. Despite missing quarterly EPS expectations, analysts maintain a \"Moderate Buy\" rating with an average price target of $21.75 for Biohaven.", "tone_signals": ["Institutional or insider buying"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 12.3, "sentiment_pct": 60, "evidence_basis": "archived_article", "evidence_share": 2.5, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.024319, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.634, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 38, "published_display": "14 Aug 2026 11:12", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "2.5", "target_provider_symbol": "BHVN", "provider_directional_mass": 0.1285}, {"url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxOUFhDdC1TOHlCdENVOUFNYThrLWJUajdMWDFKQlhYeXFRdXowV0s1MEdaQXprZUhsNmVDZm1USHR5Y1loWDluSk5GMEdMb2lCajN1bGc1WjNZaDFQMF85Z1R6VXl2ekZFa3FpRFhNTlQ3ZFZhTkZiQURQUXEyYVVoUGlCVEtqX1JsdzNPLWZETnFlbHlHT2Qxa2NSNXFXOGp2TFI4MjZLWGJZeWdyRnBrejNJTUpDZUdWT1JYSVYwUGhLUUNmY2JRYkRHSlRKSGxQZ2xTa3ZpSVZ4QTZqMXdKamt4eF9tbU1pMmpKRERVLWE?oc=5", "tier": "direct", "title": "Bank of America Securities Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN)", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Bank of America Securities has reiterated a Buy rating on Biohaven Ltd. (BHVN) with a price target of $11.00, despite the stock closing higher at $14.54. Analyst Dina Ramadane, who covers the Healthcare sector, has a 61.54% success rate on her recommendations. The broader analyst consensus for Biohaven Ltd. is a Moderate Buy with an average price target of $16.33.", "age_days": 17.3, "is_stale": false, "provider": "google_news", "providers": ["alphavantage", "google_news"], "sentiment": "positive", "story_key": "6e4cc5e2601a0265826fe6ff6e847dd327fb33a3d2485ccb73a6830b9b9a92b7", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxOUFhDdC1TOHlCdENVOUFNYThrLWJUajdMWDFKQlhYeXFRdXowV0s1MEdaQXprZUhsNmVDZm1USHR5Y1loWDluSk5GMEdMb2lCajN1bGc1WjNZaDFQMF85Z1R6VXl2ekZFa3FpRFhNTlQ3ZFZhTkZiQURQUXEyYVVoUGlCVEtqX1JsdzNPLWZETnFlbHlHT2Qxa2NSNXFXOGp2TFI4MjZLWGJZeWdyRnBrejNJTUpDZUdWT1JYSVYwUGhLUUNmY2JRYkRHSlRKSGxQZ2xTa3ZpSVZ4QTZqMXdKamt4eF9tbU1pMmpKRERVLWE?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-08-12T07:00:00+00:00", "source_names": ["The Globe and Mail"], "target_scope": "Bank of America Securities Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN) Bank of America Securities has reiterated a Buy rating on Biohaven Ltd. (BHVN) with a price target of $11.00, despite the stock closing higher at $14.54. The broader analyst consensus for Biohaven Ltd.", "tone_signals": ["Buy Rating"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 1.8, "sentiment_pct": 72, "evidence_basis": "archived_article", "evidence_share": 0.4, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.003916, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 69, "model_confidence": 0.668, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 46, "published_display": "12 Aug 2026 07:00", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.4", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://m.investing.com/news/analyst-ratings/biohaven-pharma-stock-price-target-raised-to-23-by-rbc-capital-93CH-4852142?ampMode=1", "tier": "direct", "title": "Biohaven Pharma stock price target raised to $23 by RBC Capital", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "RBC Capital has raised its price target for Biohaven Pharma (NYSE:BHVN) to $23 from $22, maintaining an Outperform rating, following the company's second-quarter 2026 earnings report. The firm highlights potential opportunities in troriluzole and degrader data, estimating a more than $4 billion market by 2035, and anticipates success in the near-term Kv7 readout. Despite some elevated spending and concerns about cash burn, the pipeline is deemed attractive, and the company is progressing with other trials like RISE3 for epilepsy and a Phase 3 trial for Graves\u2019 disease.", "age_days": 18.0, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "positive", "story_key": "ba6b3e2622572944c1ae7a0e61f2107e45b5a568a29b91eeca06d42a3b4a0ec6", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://m.investing.com/news/analyst-ratings/biohaven-pharma-stock-price-target-raised-to-23-by-rbc-capital-93CH-4852142?ampMode=1", "source_name": "Investing.com", "published_at": "2026-08-11T14:44:42+00:00", "source_names": ["Investing.com"], "target_scope": "Biohaven Pharma stock price target raised to $23 by RBC Capital RBC Capital has raised its price target for Biohaven Pharma (NYSE:BHVN) to $23 from $22, maintaining an Outperform rating, following the company's second-quarter 2026 earnings report.", "tone_signals": ["Analyst upgrade"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 1.6, "sentiment_pct": 75, "evidence_basis": "archived_article", "evidence_share": 0.5, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.005033, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 0.997473, "archive_provider": "alphavantage", "event_confidence": 96, "model_confidence": 0.695, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 49, "published_display": "11 Aug 2026 14:44", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.5", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOd0s0Z3BLWGYxUmdSeGt1N1RIQkNSZzM5UXl4V3BBS0xRUXZ3MVlzZGdJcUFlZVMxT1BPbVd4alVLVTJVRWVwbUNxaXBaNkhJelJfNVkxNTYyWExYX2lVUG9Pc1RDUXBrUElYb05DVFBvRzR4eFZXTGlpejNzZTNvdDBSSE9KR2JHbGdscl9yZ1BPekFXSU9PcHM1cUVsN2ln?oc=5", "tier": "direct", "title": "Biohaven (BHVN) Holds Near Key Support After Modest Pullback - Pre-Earnings Momentum", "topics": [], "summary": "", "age_days": 18.3, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "5d93bad99c8164cd80eacdc4af79d053e2ff9193ebcbd05f7ab3b57a3ea2375c", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOd0s0Z3BLWGYxUmdSeGt1N1RIQkNSZzM5UXl4V3BBS0xRUXZ3MVlzZGdJcUFlZVMxT1BPbVd4alVLVTJVRWVwbUNxaXBaNkhJelJfNVkxNTYyWExYX2lVUG9Pc1RDUXBrUElYb05DVFBvRzR4eFZXTGlpejNzZTNvdDBSSE9KR2JHbGdscl9yZ1BPekFXSU9PcHM1cUVsN2ln?oc=5", "source_name": "vinanet.vn", "published_at": "2026-08-11T07:00:00+00:00", "source_names": ["vinanet.vn"], "target_scope": "Biohaven (BHVN) Holds Near Key Support After Modest Pullback - Pre-Earnings Momentum", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.2, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 9.4e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Aug 2026 07:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.stocktitan.net/sec-filings/BHVN/10-q-biohaven-ltd-quarterly-earnings-report-6b7da5e6453e.html", "tier": "direct", "title": "Biohaven (NYSE: BHVN) reports $267.8M H1 2026 loss and $267.9M in liquidity", "topics": ["Earnings", "Life Sciences"], "summary": "Biohaven Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company, reported a net loss of $267.8 million for the first half of 2026, primarily due to $204.6 million in research and development expenses. The company maintains liquidity with $267.9 million in cash, cash equivalents, and marketable securities, which management expects to fund operations for at least one year. Biohaven is focused on advancing its R&D portfolio across immunology, obesity, neuroscience, and oncology, including key clinical programs such as Kv7 ion channel modulation for epilepsy and Molecular Degrader of Extracellular Proteins (MoDE) for immunological diseases.", "age_days": 18.3, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "negative", "story_key": "86e68bfe7b5de72fa4b80439f64c6b7779f8054ad82832f67a20c9554a4cc962", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.stocktitan.net/sec-filings/BHVN/10-q-biohaven-ltd-quarterly-earnings-report-6b7da5e6453e.html", "source_name": "Stock Titan", "published_at": "2026-08-11T06:15:38+00:00", "source_names": ["Stock Titan"], "target_scope": "Biohaven (NYSE: BHVN) reports $267.8M H1 2026 loss and $267.9M in liquidity Biohaven Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company, reported a net loss of $267.8 million for the first half of 2026, primarily due to $204.6 million in research and development expenses. Biohaven is focused on advancing its R&D portfolio across immunology, obesity, neuroscience, and oncology, including key clinical programs such as Kv7 ion channel modulation for epilepsy and Molecular Degrader of Extracellular Proteins (MoDE) for immunological diseases.", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 7.9, "sentiment_pct": 41, "evidence_basis": "archived_article", "evidence_share": 1.2, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.011475, "influence_label": "Low", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 53, "model_confidence": 0.481, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 34, "published_display": "11 Aug 2026 06:15", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "1.2", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.marketbeat.com/instant-alerts/biohaven-nysebhvn-posts-quarterly-earnings-results-misses-estimates-by-002-eps-2026-08-10", "tier": "direct", "title": "Biohaven (NYSE:BHVN) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Biohaven (NYSE:BHVN) announced its quarterly earnings, reporting a loss of $0.78 per share, which missed analysts' consensus estimates by $0.02. Following the announcement, shares of Biohaven dropped 0.5% to $14.58. Despite the earnings miss, analyst sentiment for Biohaven remains a \"Moderate Buy\" with an average price target of $21.62.", "age_days": 18.6, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "negative", "story_key": "252ecb0f0da33ac582ce12a0ac8622c6aa329044dc3abbf012b4af164fade1ba", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/instant-alerts/biohaven-nysebhvn-posts-quarterly-earnings-results-misses-estimates-by-002-eps-2026-08-10", "source_name": "MarketBeat", "published_at": "2026-08-10T23:15:38+00:00", "source_names": ["MarketBeat"], "target_scope": "Biohaven (NYSE:BHVN) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS Biohaven (NYSE:BHVN) announced its quarterly earnings, reporting a loss of $0.78 per share, which missed analysts' consensus estimates by $0.02. Following the announcement, shares of Biohaven dropped 0.5% to $14.58. Despite the earnings miss, analyst sentiment for Biohaven remains a \"Moderate Buy\" with an average price target of $21.62.", "tone_signals": ["Missed expectations", "Negative market reaction", "Large negative market reaction"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 7.6, "sentiment_pct": 16, "evidence_basis": "archived_article", "evidence_share": 3.2, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.030842, "influence_label": "High", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 93, "model_confidence": 0.84, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 63, "published_display": "10 Aug 2026 23:15", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "3.2", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.marketbeat.com/instant-alerts/filing-biohaven-ltd-bhvn-shares-purchased-by-the-manufacturers-life-insurance-company-2026-08-10", "tier": "direct", "title": "Biohaven Ltd. $BHVN Shares Purchased by The Manufacturers Life Insurance Company", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "The Manufacturers Life Insurance Company increased its stake in Biohaven Ltd. (NYSE:BHVN) by 52.5% in Q1, now owning 202,975 shares valued at $1.72 million. Other institutional investors also significantly increased their holdings, with hedge funds and institutional investors collectively owning 88.78% of the stock. Analysts currently rate Biohaven as a \"Moderate Buy\" with an average price target of $21.62.", "age_days": 18.8, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "positive", "story_key": "840e5db061c5e37ac700ae6bbb52340d2e57d8e429d032c87eede8697fb02092", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.marketbeat.com/instant-alerts/filing-biohaven-ltd-bhvn-shares-purchased-by-the-manufacturers-life-insurance-company-2026-08-10", "source_name": "MarketBeat", "published_at": "2026-08-10T20:09:36+00:00", "source_names": ["MarketBeat"], "target_scope": "Biohaven Ltd. $BHVN Shares Purchased by The Manufacturers Life Insurance Company The Manufacturers Life Insurance Company increased its stake in Biohaven Ltd. (NYSE:BHVN) by 52.5% in Q1, now owning 202,975 shares valued at $1.72 million. Analysts currently rate Biohaven as a \"Moderate Buy\" with an average price target of $21.62.", "tone_signals": ["Institutional or insider buying"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 7.4, "sentiment_pct": 60, "evidence_basis": "archived_article", "evidence_share": 1.5, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.014709, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 53, "model_confidence": 0.634, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 37, "published_display": "10 Aug 2026 20:09", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "1.5", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://kalkinemedia.com/us/news/announcements/biohaven-ltd-announces-q2-2026-financial-results-highlighting-reduced-losses-and-rd-spending", "tier": "direct", "title": "Biohaven Ltd. Announces Q2 2026 Financial Results Highlighting Reduced Losses and R&D Spending", "topics": ["Earnings", "Life Sciences"], "summary": "Biohaven Ltd. has filed its Q2 2026 financial report, revealing continued operating losses but also a reduction in research and development spending compared to the previous year. This report covers the three- and six-month periods ending June 30, 2026. The full details are available via an SEC Form 10-Q filing.", "age_days": 19.0, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "positive", "story_key": "68a78205a3b44fcb2c04c5fdce882620d1734afde121c9282230cf46056fa69f", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://kalkinemedia.com/us/news/announcements/biohaven-ltd-announces-q2-2026-financial-results-highlighting-reduced-losses-and-rd-spending", "source_name": "Kalkine Media", "published_at": "2026-08-10T14:16:00+00:00", "source_names": ["Kalkine Media"], "target_scope": "Biohaven Ltd. Biohaven Ltd.", "tone_signals": ["Loss narrowed"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 7.2, "sentiment_pct": 66, "evidence_basis": "archived_article", "evidence_share": 1.5, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.014322, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 53, "model_confidence": 0.557, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 42, "published_display": "10 Aug 2026 14:16", "direction_included": true, "sentiment_conflict": 0.118, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "1.5", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxORUFxb2RXeWJiVjlxVVozSTdvQS1mLVZaM2lGZ2d2ZHpWOHlkcmMzbWZadGNoZWg5M184RUxFbHI1bW5QUHEwYjdMODBaUWxacWZfZmJzSVVrTGZSU1pnQ2ozQ0EwRmEyWmVJZEgxdENrX2xTNzVSVWw4TVdDb1U2OHBvZDdtcGRWeXl5RGZTbGZGTzk3WXhHRlRCYi1BeHVONGVOemVfRHUzempyQm5TWXFJZEtfeVZRR0p6SDdLWFJ1elRobTd1akRjTFdtcFZDUllSVDNob1V6NTA?oc=5", "tier": "direct", "title": "Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results", "topics": ["AUTOIMMUNE-DISEASES", "Autoimmune Diseases", "BIOPHARMA", "Biopharma", "CLINICAL-TRIALS", "Clinical Trials"], "summary": "First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed, Phase 3 trial underway Positive clinical biomarker and patient data presented from Biohaven's extracellular degrader platform demonstrated deep, rapid, selective lowering of disease-driving antibodies with BHV-1300 in Graves' disease and BHV-1400 IgA Nephropathy, supporting advancement toward multiple registrational programs. Initiated pivotal Phase 3 study for BHV-1300 in Graves' disease with plans to initiate pivotal Phase 3 study for", "age_days": 19.3, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "46b6acfea20a6c6d87177b86e9eacc040ed5d675bb2f5fa16298325bbfc77e7c", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "press_release", "source_link": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxORUFxb2RXeWJiVjlxVVozSTdvQS1mLVZaM2lGZ2d2ZHpWOHlkcmMzbWZadGNoZWg5M184RUxFbHI1bW5QUHEwYjdMODBaUWxacWZfZmJzSVVrTGZSU1pnQ2ozQ0EwRmEyWmVJZEgxdENrX2xTNzVSVWw4TVdDb1U2OHBvZDdtcGRWeXl5RGZTbGZGTzk3WXhHRlRCYi1BeHVONGVOemVfRHUzempyQm5TWXFJZEtfeVZRR0p6SDdLWFJ1elRobTd1akRjTFdtcFZDUllSVDNob1V6NTA?oc=5", "source_name": "PR Newswire", "published_at": "2026-08-10T07:00:00+00:00", "source_names": ["PR Newswire"], "target_scope": "Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed, Phase 3 trial underway Positive clinical biomarker and patient data presented from Biohaven's extracellular degrader platform demonstrated deep, rapid, selective lowering of disease-driving antibodies with BHV-1300 in Graves' disease and BHV-1400 IgA Nephropathy, supporting advancement toward multiple registrational programs.", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 6.9, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.008428, "influence_label": "None", "provider_symbol": "BHVN.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.45, "provider_symbols": ["BHVN.ARCHIVE", "BHVN.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "10 Aug 2026 07:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://m.investing.com/news/earnings/biohaven-earnings-set-to-show-cash-burn-ahead-of-epilepsy-data-93CH-4847742?ampMode=1", "tier": "direct", "title": "Biohaven earnings set to show cash burn ahead of epilepsy data", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Biohaven Pharmaceutical Holding Co Ltd is expected to report its second-quarter earnings, with analysts forecasting a narrower loss of 75 cents per share. Investors will be closely watching the company's cash burn rate and updates on its epilepsy drug candidate, opakalim, which has topline results expected in the second half of 2026. The stock faces skepticism from some analysts due to competitive concerns and cash runway, while others maintain a positive outlook.", "age_days": 20.0, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "positive", "story_key": "9dda0b9a824abb31b007b659aee4b5c67b56e4b3a7b706b90db858eabb88f3ab", "event_type": "liquidity", "tier_label": "Direct company coverage", "event_label": "Balance sheet", "source_kind": "publisher", "source_link": "https://m.investing.com/news/earnings/biohaven-earnings-set-to-show-cash-burn-ahead-of-epilepsy-data-93CH-4847742?ampMode=1", "source_name": "Investing.com", "published_at": "2026-08-09T13:10:06+00:00", "source_names": ["Investing.com"], "target_scope": "Biohaven earnings set to show cash burn ahead of epilepsy data Biohaven Pharmaceutical Holding Co Ltd is expected to report its second-quarter earnings, with analysts forecasting a narrower loss of 75 cents per share.", "tone_signals": ["Beat expectations"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 13.7, "sentiment_pct": 76, "evidence_basis": "archived_article", "evidence_share": 5.9, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.056734, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 77, "model_confidence": 0.618, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 54, "published_display": "09 Aug 2026 13:10", "direction_included": true, "sentiment_conflict": 0.064, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "5.9", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTFBELVhFeFlqNWozQXltSXhHSEl2OFczc1ZnLS03MHBfYlJ5X0ZsUEt4M2FyZk1BdFZPOG5PVDlPaWRVejdoYU1WcXJpR1gwenBJM3RqTzV4dW81ckI3RUVKaXFUWnNNQQ?oc=5", "tier": "direct", "title": "Biohaven Ltd (BHVN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "topics": [], "summary": "", "age_days": 20.3, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "positive", "story_key": "dc14c048f9499c6887b768a54ca3d6a067818bc25a92ec30028c7957971ee8b1", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiZkFVX3lxTFBELVhFeFlqNWozQXltSXhHSEl2OFczc1ZnLS03MHBfYlJ5X0ZsUEt4M2FyZk1BdFZPOG5PVDlPaWRVejdoYU1WcXJpR1gwenBJM3RqTzV4dW81ckI3RUVKaXFUWnNNQQ?oc=5", "source_name": "TradingKey", "published_at": "2026-08-09T07:00:00+00:00", "source_names": ["TradingKey"], "target_scope": "Biohaven Ltd (BHVN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "tone_signals": ["Growth forecast"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 6.0, "sentiment_pct": 59, "evidence_basis": "headline_only", "evidence_share": 0.9, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.008544, "influence_label": "Low", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 69, "model_confidence": 0.542, "provider_symbols": ["BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 35, "published_display": "09 Aug 2026 07:00", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.9", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.stocktradersdaily.com/news_release/12/Understanding_Momentum_Shifts_in_BHVN_080926051002_1786266602.html", "tier": "direct", "title": "Understanding Momentum Shifts in (BHVN)", "topics": ["Financial Markets", "Life Sciences"], "summary": "This article analyzes Biohaven Ltd. (BHVN) stock, highlighting a potential shift where strong near-term sentiment might challenge persistent mid and long-term weakness. It identifies resistance testing and outlines three AI-generated trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014with specific entry, target, and stop-loss zones for different risk profiles. The analysis emphasizes risk-reward scenarios and multi-timeframe signal insights.", "age_days": 20.4, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "67a9cea3df7044c49fd6b0545d59b762d8e4ca6b207f1bdab4ff04c9762101c3", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.stocktradersdaily.com/news_release/12/Understanding_Momentum_Shifts_in_BHVN_080926051002_1786266602.html", "source_name": "Stock Traders Daily", "published_at": "2026-08-09T05:11:35+00:00", "source_names": ["Stock Traders Daily"], "target_scope": "Understanding Momentum Shifts in (BHVN) This article analyzes Biohaven Ltd. (BHVN) stock, highlighting a potential shift where strong near-term sentiment might challenge persistent mid and long-term weakness.", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 6e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 35, "model_confidence": 0.45, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "09 Aug 2026 05:11", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.marketscreener.com/news/biohaven-ltd-announces-appointment-of-john-yetimoglu-to-board-of-directors-effective-august-6-202-ce7f50dddb81f222", "tier": "direct", "title": "Biohaven Ltd. Announces Appointment of John Yetimoglu to Board of Directors, Effective August 6, 2026", "topics": ["Finance", "Life Sciences", "Technology"], "summary": "Biohaven Ltd. has announced the appointment of John Yetimoglu to its Board of Directors and as a member of the Nominating and Governance Committee, effective August 6, 2026. Mr. Yetimoglu, founder and CIO of Infinitum, brings expertise in semiconductors, videogaming, and AI application platforms. His appointment is expected to enhance the company's strategic oversight in leveraging AI and advanced computational methods for medical breakthroughs.", "age_days": 22.1, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "d3190d7efcca87641fcd8176475d2c89a9c404e1a09ac7126a7de8fcac35b52e", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.marketscreener.com/news/biohaven-ltd-announces-appointment-of-john-yetimoglu-to-board-of-directors-effective-august-6-202-ce7f50dddb81f222", "source_name": "www.marketscreener.com", "published_at": "2026-08-07T11:40:51+00:00", "source_names": ["www.marketscreener.com"], "target_scope": "Biohaven Ltd. Biohaven Ltd.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 2.9e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "07 Aug 2026 11:40", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.morningstar.com/news/pr-newswire/20260806ne20330/biohaven-appoints-technology-investor-john-yetimoglu-to-board-of-directors", "tier": "direct", "title": "Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors", "topics": ["AI", "Appointments", "Biopharmaceuticals", "Drug Development", "Finance", "Life Sciences"], "summary": "Biohaven Ltd. (NYSE: BHVN) has appointed John Yetimoglu, founder and CIO of Infinitum and a board director at Groq, to its Board of Directors. Yetimoglu brings extensive experience in frontier AI and technology investing, which Biohaven anticipates will strengthen its strategic oversight as it integrates AI, machine learning, and advanced computational methods into drug discovery and development. This appointment highlights Biohaven's belief in the convergence of biology, data, and computation to drive future medical breakthroughs.", "age_days": 22.3, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "e50ae12d4357f1a2eb4605b2b2de84de5571de7e8d16d6a84f90ccac14d4b35e", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.morningstar.com/news/pr-newswire/20260806ne20330/biohaven-appoints-technology-investor-john-yetimoglu-to-board-of-directors", "source_name": "Morningstar", "published_at": "2026-08-07T06:15:38+00:00", "source_names": ["Morningstar"], "target_scope": "Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors Biohaven Ltd. (NYSE: BHVN) has appointed John Yetimoglu, founder and CIO of Infinitum and a board director at Groq, to its Board of Directors. Yetimoglu brings extensive experience in frontier AI and technology investing, which Biohaven anticipates will strengthen its strategic oversight as it integrates AI, machine learning, and advanced computational methods into drug discovery and development. This appointment highlights Biohaven's belief in the convergence of biology, data, and computation to drive future medical breakthroughs.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 3.7e-05, "influence_label": "None", "provider_symbol": "BHVN.US", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["BHVN", "BHVN.ARCHIVE", "BHVN.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "07 Aug 2026 06:15", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://ca.finance.yahoo.com/quote/BHVN", "tier": "direct", "title": "Biohaven Ltd. (BHVN) Stock Price, News, Quote & History", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "summary": "This Yahoo Finance page provides detailed stock information for Biohaven Ltd. (BHVN), including its current stock price, historical data, key events, and financial metrics. The company, a biopharmaceutical firm, focuses on treatments for immunology, neuroscience, and oncology, with several drug candidates in various clinical trial phases. The page also offers analyst insights, performance comparisons against the S&P 500, and a list of similar biotechnology companies.", "age_days": 22.7, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "2f2bcd647c317d36a87bef316ccfdad561818c75eef0264d0ac822998b46f5a2", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://ca.finance.yahoo.com/quote/BHVN", "source_name": "Yahoo! Finance Canada", "published_at": "2026-08-06T21:40:59+00:00", "source_names": ["Yahoo! Finance Canada"], "target_scope": "Biohaven Ltd. (BHVN) Stock Price, News, Quote & History This Yahoo Finance page provides detailed stock information for Biohaven Ltd. (BHVN), including its current stock price, historical data, key events, and financial metrics.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 4.3, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.003541, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "alphavantage", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "06 Aug 2026 21:40", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/biohaven-bhvn-adds-ai-expertise-to-its-board-is-the-valuatio", "tier": "direct", "title": "Biohaven (BHVN) Adds AI Expertise To Its Board, Is The Valuation Gap Too Wide?", "topics": ["Earnings", "Financial Markets", "Life Sciences", "Technology"], "summary": "Biohaven (BHVN) recently appointed John Yetimoglu, an AI-focused investment leader, to its Board, signaling a stronger push into data-driven drug discovery. Despite recent stock volatility, a Discounted Cash Flow (DCF) model suggests Biohaven is significantly undervalued at $13.63, with a fair value estimate of $58.37 per share, driven by high future growth assumptions. However, its high Price-to-Book (P/B) ratio of 15.8x compared to industry averages and risks like limited cash runway and potential shareholder dilution present a mixed valuation picture.", "age_days": 22.8, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "bc11dfef7063eace5085a5d93712a9f407c6b720d246af7e40f71c3677984ca9", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/biohaven-bhvn-adds-ai-expertise-to-its-board-is-the-valuatio", "source_name": "Simply Wall St", "published_at": "2026-08-06T19:40:00+00:00", "source_names": ["Simply Wall St"], "target_scope": "Biohaven (BHVN) Adds AI Expertise To Its Board, Is The Valuation Gap Too Wide? Biohaven (BHVN) recently appointed John Yetimoglu, an AI-focused investment leader, to its Board, signaling a stronger push into data-driven drug discovery. Despite recent stock volatility, a Discounted Cash Flow (DCF) model suggests Biohaven is significantly undervalued at $13.63, with a fair value estimate of $58.37 per share, driven by high future growth assumptions.", "tone_signals": ["Dilution risk", "Positive valuation view"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 4.3, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.005014, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "alphavantage", "event_confidence": 53, "model_confidence": 0.573, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "06 Aug 2026 19:40", "direction_included": false, "sentiment_conflict": 0.27, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.citybiz.co/article/885111/biohaven-adds-technology-investor-john-yetimoglu-to-board-as-ai-strategy-advances", "tier": "direct", "title": "Biohaven Adds Technology Investor John Yetimoglu to Board as AI Strategy Advances", "topics": ["Life Sciences", "Technology"], "summary": "Biohaven Ltd. (NYSE: BHVN) has appointed technology investor John Yetimoglu to its Board of Directors to bolster its artificial intelligence and computational technologies strategy in drug discovery and development. Yetimoglu, founder of Infinitum and an early investor in Groq, brings extensive experience in emerging technologies and AI infrastructure to the biopharmaceutical company. This appointment reflects a growing trend in the life sciences industry to integrate AI expertise at the board level to accelerate innovation and decision-making.", "age_days": 23.1, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "7c41a4ddf06dfe0048a9510b9530dd023145c3600738184393e1de148972f467", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.citybiz.co/article/885111/biohaven-adds-technology-investor-john-yetimoglu-to-board-as-ai-strategy-advances", "source_name": "citybiz", "published_at": "2026-08-06T12:16:53+00:00", "source_names": ["citybiz"], "target_scope": "Biohaven Adds Technology Investor John Yetimoglu to Board as AI Strategy Advances Biohaven Ltd. (NYSE: BHVN) has appointed technology investor John Yetimoglu to its Board of Directors to bolster its artificial intelligence and computational technologies strategy in drug discovery and development.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 2.1e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["BHVN", "BHVN.ARCHIVE", "MS", "NVDA"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "06 Aug 2026 12:16", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOa0w5ZmEyV0I4dUxEY1JZdkFJNm82Zy14Q1JUcHNzZWJsNHQzNi1IZWZGSmV3UnVFY01TTDBpS1FsWV83TzRzTEw0cWZlZmFfXzY0ejEwb2VvN0UxUG4xLTBRRENwaEZPN0Y0RlBPMlVPSWNJMkVMdV9IUUNjbmNGZElMYTl6bmVuQ2VZZ3c4c3NJb2tROHRLZVZ6OTFKTVgwVF9rbUVqVlhfSmIxdExDbDhJUHZhcFU?oc=5", "tier": "direct", "title": "Biohaven (BHVN) Expected to Release Quarterly Earnings on Monday", "topics": [], "summary": "", "age_days": 26.0, "is_stale": false, "provider": "archive", "providers": ["archive", "google_news"], "sentiment": "neutral", "story_key": "0b908c2e3cf4b6df96ff3fabec9d55a9709c8ca7ae5262f4ab15ac7bb2d8c664", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOa0w5ZmEyV0I4dUxEY1JZdkFJNm82Zy14Q1JUcHNzZWJsNHQzNi1IZWZGSmV3UnVFY01TTDBpS1FsWV83TzRzTEw0cWZlZmFfXzY0ejEwb2VvN0UxUG4xLTBRRENwaEZPN0Y0RlBPMlVPSWNJMkVMdV9IUUNjbmNGZElMYTl6bmVuQ2VZZ3c4c3NJb2tROHRLZVZ6OTFKTVgwVF9rbUVqVlhfSmIxdExDbDhJUHZhcFU?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-03T13:30:02+00:00", "source_names": ["MarketBeat"], "target_scope": "Biohaven (BHVN) Expected to Release Quarterly Earnings on Monday", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 2.7, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.002229, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "03 Aug 2026 13:30", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNSnVmQ3JuRnkxWTh6V0hMSDd2SF94eHRBSXJmQTFxOWlKTVRNbXgyZkMwNkVzRFQya3NxYkFjNDZHNVdSMHpiZnhfRi1URmxOVnRPd0N3R242WjFUbkNpQ0FnWjM5NHhfdlJTc0lnNkFOanRkZmtCY1YxTjdLbHlUUmM0S05WaXI2bmJwUjNibUxsX0FuSkJlNkREZkU5b01mUGhxc0lJbUlqa0h3RDM1ZEJ2clJwQTQ2QW9scG8zXzVyYU1OSHlJWElPQQ?oc=5", "tier": "direct", "title": "Defilade Capital Management L.P. Buys Shares of 315,944 Biohaven Ltd. $BHVN", "topics": [], "summary": "", "age_days": 26.3, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "positive", "story_key": "b35108aa18389dde8e351148d16dfaa4bc843589c8ae05477bd99bc6c266dcea", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNSnVmQ3JuRnkxWTh6V0hMSDd2SF94eHRBSXJmQTFxOWlKTVRNbXgyZkMwNkVzRFQya3NxYkFjNDZHNVdSMHpiZnhfRi1URmxOVnRPd0N3R242WjFUbkNpQ0FnWjM5NHhfdlJTc0lnNkFOanRkZmtCY1YxTjdLbHlUUmM0S05WaXI2bmJwUjNibUxsX0FuSkJlNkREZkU5b01mUGhxc0lJbUlqa0h3RDM1ZEJ2clJwQTQ2QW9scG8zXzVyYU1OSHlJWElPQQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-03T07:00:00+00:00", "source_names": ["MarketBeat"], "target_scope": "Buys Shares of 315,944 Biohaven Ltd. $BHVN", "tone_signals": ["Institutional or insider buying"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 58, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 1e-05, "influence_label": "Low", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.539, "provider_symbols": ["BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 30, "published_display": "03 Aug 2026 07:00", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "<0.1", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPdTJNd1ctbkdrdC1aNHR6YmxuaXFTdDA0Rm1GS3N5clY0dUROdjNEdWNqYjFkZFdFWDRTUGxfOU10Z0xwWkFrQ3JQX1B3SEI3ZmRHWlM0MWVlYXBGaml5NHdROEg2NzRtcFgyQk9ZeDMtYkJKWGIwaXJEYVduSzNKaVpTWmxOZmUtR0VRR2VYQVdWdGJ6MFBRWmstQ19rY1ZPUDJYcXNvS2VKY1NzajV4WGR5emVxYmR2MlE?oc=5", "tier": "direct", "title": "BHVN Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline Spending Intensifies - Growth Acceleration Report", "topics": [], "summary": "", "age_days": 27.3, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "negative", "story_key": "cd595bdf79f0661b3617aeb68ae97eb1d8b81ddb22cf00d04497af95df27740d", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPdTJNd1ctbkdrdC1aNHR6YmxuaXFTdDA0Rm1GS3N5clY0dUROdjNEdWNqYjFkZFdFWDRTUGxfOU10Z0xwWkFrQ3JQX1B3SEI3ZmRHWlM0MWVlYXBGaml5NHdROEg2NzRtcFgyQk9ZeDMtYkJKWGIwaXJEYVduSzNKaVpTWmxOZmUtR0VRR2VYQVdWdGJ6MFBRWmstQ19rY1ZPUDJYcXNvS2VKY1NzajV4WGR5emVxYmR2MlE?oc=5", "source_name": "vinanet.vn", "published_at": "2026-08-02T07:00:00+00:00", "source_names": ["vinanet.vn"], "target_scope": "BHVN Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline Spending Intensifies - Growth Acceleration Report", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 2.3, "sentiment_pct": 43, "evidence_basis": "headline_only", "evidence_share": 0.3, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.002591, "influence_label": "Low", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 53, "model_confidence": 0.461, "provider_symbols": ["BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 31, "published_display": "02 Aug 2026 07:00", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.3", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPME1PMDUzYWFranR5eGwxTjZucGsyWGo1cXc0cDYyaDR4bmM5QXMtRTJybE1HQ1M1LW9iYWpNYkZjMmVXdnVzd0dGWHlQaTVJcWhqSXdZYnk3VEJ4ckptSXFjUnE0TTJ3bjZLcHJKUTNoMUx3WXJhQWpwUEJoSHB1dndkcDdmTzBKVmlxOUdQalFUUVd2aEZjWjlybTdvNmJuRGJHNkRxbGlQYThEenBiN2RaN29GaVpHZGRMR3BB?oc=5", "tier": "direct", "title": "Biohaven Ltd. $BHVN Shares Bought by Janus Henderson Group PLC", "topics": [], "summary": "", "age_days": 28.3, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "positive", "story_key": "0c1b43d1b037b2ec8bd1e3898e57394b4d55bfb2bcbf15b4f596ec159a8bf298", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPME1PMDUzYWFranR5eGwxTjZucGsyWGo1cXc0cDYyaDR4bmM5QXMtRTJybE1HQ1M1LW9iYWpNYkZjMmVXdnVzd0dGWHlQaTVJcWhqSXdZYnk3VEJ4ckptSXFjUnE0TTJ3bjZLcHJKUTNoMUx3WXJhQWpwUEJoSHB1dndkcDdmTzBKVmlxOUdQalFUUVd2aEZjWjlybTdvNmJuRGJHNkRxbGlQYThEenBiN2RaN29GaVpHZGRMR3BB?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-01T07:00:00+00:00", "source_names": ["MarketBeat"], "target_scope": "Biohaven Ltd. $BHVN Shares Bought by Janus Henderson Group PLC", "tone_signals": ["Institutional or insider buying"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.0, "sentiment_pct": 58, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 5e-06, "influence_label": "Low", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.539, "provider_symbols": ["BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 30, "published_display": "01 Aug 2026 07:00", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "<0.1", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPdE9sNmt5aDB4U2tPd3BzaGhMdDh1X2doNXZCUFFZcE1OREpBdHl2b1JFbExsTWdQeXJWVWNBMTlINlpDOXIxTkx2R0NkckZxWVoxeVJRZnZnX0Nyd0cwa3Z5OXVwTUIwZ19CYmZmUDd6ZWhOS0Y5Rkc0T1JEVERfU1VJVnNfMnBIbGNHWkprbW5KTGRvYWpiUEZqbVJ1OXh0UjFiMWlNVlNhQWM?oc=5", "tier": "direct", "title": "BHVN Q1 2026 Earnings: Wider-Than-Expected Loss Sends Shares Down 2.32% - Revenue Miss Report", "topics": [], "summary": "", "age_days": 28.3, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "negative", "story_key": "5699423cf808f617779d5d43fb85edb80b21d7f1b5e1927ee571839e622f7c0e", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPdE9sNmt5aDB4U2tPd3BzaGhMdDh1X2doNXZCUFFZcE1OREpBdHl2b1JFbExsTWdQeXJWVWNBMTlINlpDOXIxTkx2R0NkckZxWVoxeVJRZnZnX0Nyd0cwa3Z5OXVwTUIwZ19CYmZmUDd6ZWhOS0Y5Rkc0T1JEVERfU1VJVnNfMnBIbGNHWkprbW5KTGRvYWpiUEZqbVJ1OXh0UjFiMWlNVlNhQWM?oc=5", "source_name": "vinanet.vn", "published_at": "2026-08-01T07:00:00+00:00", "source_names": ["vinanet.vn"], "target_scope": "BHVN Q1 2026 Earnings: Wider-Than-Expected Loss Sends Shares Down 2.32% - Revenue Miss Report", "tone_signals": ["Missed expectations"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 2.0, "sentiment_pct": 21, "evidence_basis": "headline_only", "evidence_share": 0.5, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.004745, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.621, "provider_symbols": ["BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 55, "published_display": "01 Aug 2026 07:00", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0.5", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://m.investing.com/news/earnings/biohaven-pharma-earnings-on-deck-amid-epilepsy-trial-scrutiny-93CH-4828637?ampMode=1", "tier": "direct", "title": "Biohaven Pharma earnings on deck amid epilepsy trial scrutiny", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Biohaven Pharmaceutical Holding Co. is set to report second-quarter results, with analysts anticipating a narrower loss per share. Investors will be closely watching for updates on the company's cash runway and the timeline for pivotal Phase 2/3 epilepsy trial results for its experimental drug, opakalim, especially given growing skepticism about its differentiation from rivals. The company's recent restructuring efforts and upcoming clinical data are crucial for its valuation.", "age_days": 29.0, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "9b4071744fafb7fb1a4f3c98bebf7fd720739db7b0acba4d6ce3b2d7e43f43d1", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://m.investing.com/news/earnings/biohaven-pharma-earnings-on-deck-amid-epilepsy-trial-scrutiny-93CH-4828637?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-31T14:09:20+00:00", "source_names": ["Investing.com"], "target_scope": "Biohaven Pharma earnings on deck amid epilepsy trial scrutiny Biohaven Pharmaceutical Holding Co.", "tone_signals": ["Negative financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 1.8, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.002648, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 53, "model_confidence": 0.45, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "31 Jul 2026 14:09", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.moomoo.com/news/post/73833669/biohaven-insiders-added-us-33-1m-of-stock-to-their", "tier": "direct", "title": "Biohaven Insiders Added US$33.1m Of Stock To Their Holdings", "topics": ["Earnings", "Finance", "Life Sciences"], "summary": "This article discusses recent insider purchases at Biohaven Pharmaceutical Holding Company. Insiders bought US$33.1 million worth of stock, suggesting confidence in the company's future despite a recent share price decline. The purchases come after the company's acquisition of a migraine drug by Pfizer, which resulted in a significant special dividend for shareholders.", "age_days": 29.8, "is_stale": false, "provider": "archive", "providers": ["alphavantage", "archive"], "sentiment": "neutral", "story_key": "a9484b100cfe8b76d55e93c89f0b2ef023a82f22f9279402c2a38d3e6deeed76", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.moomoo.com/news/post/73833669/biohaven-insiders-added-us-33-1m-of-stock-to-their", "source_name": "Moomoo", "published_at": "2026-07-30T20:11:24+00:00", "source_names": ["Moomoo"], "target_scope": "Biohaven Insiders Added US$33.1m Of Stock To Their Holdings This article discusses recent insider purchases at Biohaven Pharmaceutical Holding Company.", "tone_signals": ["Institutional or insider buying"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 1.6, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.001948, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "alphavantage", "event_confidence": 53, "model_confidence": 0.502, "provider_symbols": ["BHVN", "BHVN.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "30 Jul 2026 20:11", "direction_included": false, "sentiment_conflict": 0.225, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "BHVN.ARCHIVE", "provider_directional_mass": null}], "industry": [], "sector": []}, "detail_intelligence": {"headline": "Balanced news tone", "summary": "The score uses 46 current company stories from 13 publishers.", "status": "measured", "metrics": [{"label": "News score", "value": 53, "display": "53", "tone": "neutral", "note": "Balanced news tone"}, {"label": "Confidence", "value": 38, "display": "38", "tone": "neutral", "note": "thin evidence"}, {"label": "Company news", "value": 92, "display": "92%", "tone": "positive", "note": "46 company stories"}, {"label": "Story agreement", "value": 79, "display": "79", "tone": "positive", "note": "21/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 19, "note": "0.964 after freshness weighting"}, {"label": "Source breadth", "value": 100, "note": "13 independent publishers"}, {"label": "Company relevance", "value": 92, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 39, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 79, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 87, "note": "less reliance on one publisher"}], "freshness": 39, "source_independence": 87, "timeline": [{"date": "2026-08-01", "label": "01 Aug", "count": 2, "score": 21, "tone": "negative", "x": 42.0, "y": 187.8, "volume_height": 20.8, "volume_y": 245.2}, {"date": "2026-08-02", "label": "02 Aug", "count": 1, "score": 43, "tone": "neutral", "x": 73.6, "y": 147.7, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-08-03", "label": "03 Aug", "count": 2, "score": 50, "tone": "neutral", "x": 105.2, "y": 135.0, "volume_height": 20.8, "volume_y": 245.2}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 136.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 168.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 3, "score": 50, "tone": "neutral", "x": 199.9, "y": 135.0, "volume_height": 31.2, "volume_y": 234.8}, {"date": "2026-08-07", "label": "07 Aug", "count": 2, "score": 50, "tone": "neutral", "x": 231.5, "y": 135.0, "volume_height": 20.8, "volume_y": 245.2}, {"date": "2026-08-08", "label": "08 Aug", "count": 0, "score": null, "tone": "neutral", "x": 263.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 3, "score": 74, "tone": "positive", "x": 294.7, "y": 91.3, "volume_height": 31.2, "volume_y": 234.8}, {"date": "2026-08-10", "label": "10 Aug", "count": 4, "score": 40, "tone": "negative", "x": 326.3, "y": 153.2, "volume_height": 41.6, "volume_y": 224.4}, {"date": "2026-08-11", "label": "11 Aug", "count": 3, "score": 51, "tone": "neutral", "x": 357.9, "y": 133.2, "volume_height": 31.2, "volume_y": 234.8}, {"date": "2026-08-12", "label": "12 Aug", "count": 1, "score": 72, "tone": "positive", "x": 389.4, "y": 95.0, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-08-13", "label": "13 Aug", "count": 0, "score": null, "tone": "neutral", "x": 421.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-14", "label": "14 Aug", "count": 4, "score": 47, "tone": "neutral", "x": 452.6, "y": 140.5, "volume_height": 41.6, "volume_y": 224.4}, {"date": "2026-08-15", "label": "15 Aug", "count": 1, "score": 70, "tone": "positive", "x": 484.2, "y": 98.6, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-08-16", "label": "16 Aug", "count": 1, "score": 58, "tone": "positive", "x": 515.8, "y": 120.4, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-08-17", "label": "17 Aug", "count": 0, "score": null, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-18", "label": "18 Aug", "count": 0, "score": null, "tone": "neutral", "x": 579.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-19", "label": "19 Aug", "count": 1, "score": 46, "tone": "neutral", "x": 610.6, "y": 142.3, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-08-20", "label": "20 Aug", "count": 0, "score": null, "tone": "neutral", "x": 642.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-21", "label": "21 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 673.7, "y": 135.0, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-08-22", "label": "22 Aug", "count": 2, "score": 38, "tone": "negative", "x": 705.3, "y": 156.8, "volume_height": 20.8, "volume_y": 245.2}, {"date": "2026-08-23", "label": "23 Aug", "count": 0, "score": null, "tone": "neutral", "x": 736.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-24", "label": "24 Aug", "count": 2, "score": 55, "tone": "neutral", "x": 768.5, "y": 125.9, "volume_height": 20.8, "volume_y": 245.2}, {"date": "2026-08-25", "label": "25 Aug", "count": 3, "score": 50, "tone": "neutral", "x": 800.1, "y": 135.0, "volume_height": 31.2, "volume_y": 234.8}, {"date": "2026-08-26", "label": "26 Aug", "count": 5, "score": 47, "tone": "neutral", "x": 831.7, "y": 140.5, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-27", "label": "27 Aug", "count": 2, "score": 73, "tone": "positive", "x": 863.2, "y": 93.1, "volume_height": 20.8, "volume_y": 245.2}, {"date": "2026-08-28", "label": "28 Aug", "count": 1, "score": 50, "tone": "neutral", "x": 894.8, "y": 135.0, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-08-29", "label": "29 Aug", "count": 0, "score": null, "tone": "neutral", "x": 926.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-30", "label": "30 Aug", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "42.0,187.8 73.6,147.7 105.2,135.0 199.9,135.0 231.5,135.0 294.7,91.3 326.3,153.2 357.9,133.2 389.4,95.0 452.6,140.5 484.2,98.6 515.8,120.4 610.6,142.3 673.7,135.0 705.3,156.8 768.5,125.9 800.1,135.0 831.7,140.5 863.2,93.1 894.8,135.0", "timeline_has_signal": true, "timeline_start": "01 Aug", "timeline_mid": "16 Aug", "timeline_end": "30 Aug", "momentum": {"label": "Tentative improvement", "tone": "neutral", "recent_score": 71, "prior_score": 49, "delta": 22, "recent_count": 3, "prior_count": 10, "volume_delta": -7, "reliable": false, "reliability_note": "Thin comparison; direction is not yet confirmed"}, "early_change": {"label": "No new story in 24 hours", "tone": "neutral", "latest_score": null, "baseline_score": 55, "delta": null, "latest_count": 0, "baseline_count": 13, "confirmed": false, "note": "A comparison needs current and earlier-week company news"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 0, "share": 0}, {"label": "1 to 3 days", "count": 3, "share": 7}, {"label": "4 to 7 days", "count": 10, "share": 22}, {"label": "8 to 14 days", "count": 5, "share": 11}, {"label": "15 to 21 days", "count": 16, "share": 35}, {"label": "22 to 30 days", "count": 11, "share": 24}], "source_profile": [{"label": "MarketBeat", "count": 9, "share": 20, "score": 47, "tone": "neutral"}, {"label": "vinanet.vn", "count": 5, "share": 11, "score": 31, "tone": "negative"}, {"label": "Investing.com", "count": 3, "share": 7, "score": 75, "tone": "positive"}, {"label": "Simply Wall Street", "count": 2, "share": 4, "score": 34, "tone": "negative"}, {"label": "PR Newswire", "count": 2, "share": 4, "score": 55, "tone": "neutral"}, {"label": "Stock Titan", "count": 2, "share": 4, "score": 47, "tone": "neutral"}, {"label": "finance.yahoo.com", "count": 2, "share": 4, "score": 50, "tone": "neutral"}], "event_profile": [{"label": "Earnings", "count": 25, "share": 54, "score": 44, "tone": "neutral"}, {"label": "Market update", "count": 9, "share": 20, "score": 50, "tone": "neutral"}, {"label": "Deals and strategy", "count": 8, "share": 17, "score": 61, "tone": "positive"}, {"label": "Analyst action", "count": 3, "share": 7, "score": 60, "tone": "positive"}, {"label": "Balance sheet", "count": 1, "share": 2, "score": 76, "tone": "positive"}], "topics": [{"label": "Life Sciences", "count": 26, "share": 57}, {"label": "Earnings", "count": 20, "share": 43}, {"label": "Financial Markets", "count": 18, "share": 39}, {"label": "Finance", "count": 10, "share": 22}, {"label": "Technology", "count": 4, "share": 9}, {"label": "Epilepsy", "count": 2, "share": 4}, {"label": "Clinical Trials", "count": 2, "share": 4}, {"label": "Biotech", "count": 2, "share": 4}, {"label": "Biopharmaceuticals", "count": 2, "share": 4}, {"label": "Balance Sheet", "count": 2, "share": 4}], "supporting": [{"label": "Direct evidence", "text": "46 current stories are mapped specifically to BHVN."}, {"label": "Source breadth", "text": "The score uses 13 publishers rather than depending on one outlet."}, {"label": "Story agreement", "text": "The current stories agree at 79/100."}], "tempering": [{"label": "Price disagreement", "text": "Price is moving more forcefully than the current news tone suggests."}], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"url": "https://finance.yahoo.com/m/16f3e772-1119-38de-adfd-c773a9f3693b/why-biohaven-stock-was.html", "tier": "direct", "title": "Why Biohaven Stock Was Rocking the Market This Week", "topics": [], "summary": "", "age_days": 1.3, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/m/16f3e772-1119-38de-adfd-c773a9f3693b/why-biohaven-stock-was.html", "source_name": "Motley Fool", "published_at": "2026-08-28T07:32:33+00:00", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 64.2, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.026318, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "28 Aug 2026 07:32", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, "article_count": 46, "updated_at": "2026-08-29T14:14:22.662668+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 173.9, "label": "06 Mar 2026", "close": 9.92, "index": 100.0}, {"x": 78.4, "y": 180.5, "label": "13 Mar 2026", "close": 9.58, "index": 96.6}, {"x": 114.9, "y": 193.2, "label": "20 Mar 2026", "close": 8.93, "index": 90.0}, {"x": 151.3, "y": 204.2, "label": "27 Mar 2026", "close": 8.37, "index": 84.4}, {"x": 187.7, "y": 176.2, "label": "03 Apr 2026", "close": 9.8, "index": 98.8}, {"x": 224.2, "y": 188.6, "label": "10 Apr 2026", "close": 9.17, "index": 92.4}, {"x": 260.6, "y": 153.2, "label": "17 Apr 2026", "close": 10.98, "index": 110.7}, {"x": 297.0, "y": 174.7, "label": "24 Apr 2026", "close": 9.88, "index": 99.6}, {"x": 333.5, "y": 179.6, "label": "01 May 2026", "close": 9.63, "index": 97.1}, {"x": 369.9, "y": 175.1, "label": "08 May 2026", "close": 9.86, "index": 99.4}, {"x": 406.3, "y": 196.6, "label": "15 May 2026", "close": 8.76, "index": 88.3}, {"x": 442.8, "y": 183.1, "label": "22 May 2026", "close": 9.45, "index": 95.3}, {"x": 479.2, "y": 152.6, "label": "29 May 2026", "close": 11.01, "index": 111.0}, {"x": 515.6, "y": 156.7, "label": "05 Jun 2026", "close": 10.8, "index": 108.9}, {"x": 552.0, "y": 147.3, "label": "12 Jun 2026", "close": 11.28, "index": 113.7}, {"x": 588.5, "y": 102.5, "label": "19 Jun 2026", "close": 13.57, "index": 136.8}, {"x": 624.9, "y": 58.3, "label": "26 Jun 2026", "close": 15.83, "index": 159.6}, {"x": 661.3, "y": 55.8, "label": "03 Jul 2026", "close": 15.96, "index": 160.9}, {"x": 697.8, "y": 63.8, "label": "10 Jul 2026", "close": 15.55, "index": 156.8}, {"x": 734.2, "y": 66.0, "label": "17 Jul 2026", "close": 15.44, "index": 155.6}, {"x": 770.6, "y": 87.9, "label": "24 Jul 2026", "close": 14.32, "index": 144.4}, {"x": 807.1, "y": 103.9, "label": "31 Jul 2026", "close": 13.5, "index": 136.1}, {"x": 843.5, "y": 81.2, "label": "07 Aug 2026", "close": 14.66, "index": 147.8}, {"x": 879.9, "y": 81.6, "label": "14 Aug 2026", "close": 14.64, "index": 147.6}, {"x": 916.4, "y": 97.1, "label": "21 Aug 2026", "close": 13.85, "index": 139.6}, {"x": 952.8, "y": 66.6, "label": "28 Aug 2026", "close": 15.41, "index": 155.3}], "sentiment_points": [{"at": "2026-05-08T23:59:59.999Z", "date": "2026-05-08", "label": "08 May 2026", "score": 50, "tone": "neutral", "raw_score": 43, "confidence": 19, "stories": 3, "close": 9.86, "price_change": 2.4, "x": 375.1, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-05-15T23:59:59.999Z", "date": "2026-05-15", "label": "15 May 2026", "score": 50, "tone": "neutral", "raw_score": 43, "confidence": 14, "stories": 3, "close": 8.76, "price_change": -11.2, "x": 411.5, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-05-22T23:59:59.999Z", "date": "2026-05-22", "label": "22 May 2026", "score": 49, "tone": "neutral", "raw_score": 43, "confidence": 28, "stories": 4, "close": 9.45, "price_change": 7.9, "x": 448.0, "y": 131.8, "show_label": false, "label_y": 121.80000000000001}, {"at": "2026-05-29T23:59:59.999Z", "date": "2026-05-29", "label": "29 May 2026", "score": 52, "tone": "neutral", "raw_score": 65, "confidence": 29, "stories": 5, "close": 11.01, "price_change": 16.5, "x": 484.4, "y": 126.3, "show_label": true, "label_y": 116.3}, {"at": "2026-06-05T23:59:59.999Z", "date": "2026-06-05", "label": "05 Jun 2026", "score": 51, "tone": "neutral", "raw_score": 65, "confidence": 20, "stories": 2, "close": 10.8, "price_change": -1.9, "x": 520.8, "y": 128.2, "show_label": false, "label_y": 118.19999999999999}, {"at": "2026-06-12T23:59:59.999Z", "date": "2026-06-12", "label": "12 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 65, "confidence": 16, "stories": 2, "close": 11.28, "price_change": 4.4, "x": 557.2, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-06-19T23:59:59.999Z", "date": "2026-06-19", "label": "19 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 65, "confidence": 15, "stories": 2, "close": 13.57, "price_change": 20.3, "x": 593.7, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 51, "tone": "neutral", "raw_score": 55, "confidence": 23, "stories": 8, "close": 15.83, "price_change": 16.7, "x": 630.1, "y": 128.2, "show_label": false, "label_y": 118.19999999999999}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 58, "confidence": 18, "stories": 10, "close": 15.96, "price_change": 0.8, "x": 666.5, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 56, "confidence": 15, "stories": 13, "close": 15.55, "price_change": -2.6, "x": 703.0, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 54, "confidence": 14, "stories": 18, "close": 15.44, "price_change": -0.7, "x": 739.4, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 43, "confidence": 21, "stories": 19, "close": 14.32, "price_change": -7.3, "x": 775.8, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 48, "confidence": 26, "stories": 30, "close": 13.5, "price_change": -5.7, "x": 812.3, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 48, "tone": "neutral", "raw_score": 38, "confidence": 23, "stories": 38, "close": 14.66, "price_change": 8.6, "x": 848.7, "y": 133.7, "show_label": false, "label_y": 123.69999999999999}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "label": "14 Aug 2026", "score": 51, "tone": "neutral", "raw_score": 52, "confidence": 42, "stories": 51, "close": 14.64, "price_change": -0.1, "x": 885.1, "y": 128.2, "show_label": false, "label_y": 118.19999999999999}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "label": "21 Aug 2026", "score": 52, "tone": "neutral", "raw_score": 54, "confidence": 29, "stories": 45, "close": 13.85, "price_change": -5.4, "x": 921.6, "y": 126.3, "show_label": true, "label_y": 116.3}, {"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "label": "28 Aug 2026", "score": 52, "tone": "neutral", "raw_score": 55, "confidence": 36, "stories": 47, "close": 15.41, "price_change": 11.3, "x": 958.0, "y": 126.3, "show_label": true, "label_y": 116.3}], "price_path": "42.0,173.9 78.4,180.5 114.9,193.2 151.3,204.2 187.7,176.2 224.2,188.6 260.6,153.2 297.0,174.7 333.5,179.6 369.9,175.1 406.3,196.6 442.8,183.1 479.2,152.6 515.6,156.7 552.0,147.3 588.5,102.5 624.9,58.3 661.3,55.8 697.8,63.8 734.2,66.0 770.6,87.9 807.1,103.9 843.5,81.2 879.9,81.6 916.4,97.1 952.8,66.6", "sentiment_path": "375.1,130.0 411.5,130.0 448.0,131.8 484.4,126.3 520.8,128.2 557.2,130.0 593.7,130.0 630.1,128.2 666.5,130.0 703.0,130.0 739.4,130.0 775.8,130.0 812.3,130.0 848.7,133.7 885.1,128.2 921.6,126.3 958.0,126.3", "score_version": "evidence-v10", "price_change": 55.3, "sentiment_change": 2, "recent_pairs": [{"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "label": "28 Aug 2026", "score": 52, "tone": "neutral", "raw_score": 55, "confidence": 36, "stories": 47, "close": 15.41, "price_change": 11.3, "x": 958.0, "y": 126.3, "show_label": true, "label_y": 116.3}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "label": "21 Aug 2026", "score": 52, "tone": "neutral", "raw_score": 54, "confidence": 29, "stories": 45, "close": 13.85, "price_change": -5.4, "x": 921.6, "y": 126.3, "show_label": true, "label_y": 116.3}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "label": "14 Aug 2026", "score": 51, "tone": "neutral", "raw_score": 52, "confidence": 42, "stories": 51, "close": 14.64, "price_change": -0.1, "x": 885.1, "y": 128.2, "show_label": false, "label_y": 118.19999999999999}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 48, "tone": "neutral", "raw_score": 38, "confidence": 23, "stories": 38, "close": 14.66, "price_change": 8.6, "x": 848.7, "y": 133.7, "show_label": false, "label_y": 123.69999999999999}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 48, "confidence": 26, "stories": 30, "close": 13.5, "price_change": -5.7, "x": 812.3, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 43, "confidence": 21, "stories": 19, "close": 14.32, "price_change": -7.3, "x": 775.8, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 54, "confidence": 14, "stories": 18, "close": 15.44, "price_change": -0.7, "x": 739.4, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 56, "confidence": 15, "stories": 13, "close": 15.55, "price_change": -2.6, "x": 703.0, "y": 130.0, "show_label": true, "label_y": 120.0}], "reconstructed": true, "latest_close": 15.41, "price_observations": 26, "sentiment_observations": 17, "sentiment_start_label": "08 May 2026", "sentiment_end_label": "28 Aug 2026", "sentiment_history_limited": false, "price_axis_high": 170.1, "price_axis_mid": 122.6, "price_axis_low": 75.2, "start_label": "06 Mar", "mid_label": "02 Jun", "end_label": "28 Aug", "live_score_version": "evidence-v10", "comparable_to_live": true}, "sentiment_history": [{"label": "04 May 23:59", "short_label": "04 May", "collected_at": "2026-05-04T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 1, "confidence": 0, "evidence_status": "insufficient", "evidence_label": "Insufficient", "score_version": "evidence-v10", "reconstructed": true}, {"label": "05 May 23:59", "short_label": "05 May", "collected_at": "2026-05-05T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 26, "article_change": 1, "tone": "neutral", "height": 4, "articles": 2, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "06 May 23:59", "short_label": "06 May", "collected_at": "2026-05-06T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 3, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "22 May 23:59", "short_label": "22 May", "collected_at": "2026-05-22T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -1, "score_change_display": "-1", "confidence_change": 3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 4, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "29 May 23:59", "short_label": "29 May", "collected_at": "2026-05-29T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 3, "score_change_display": "+3", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "21 Jun 23:59", "short_label": "21 Jun", "collected_at": "2026-06-21T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -2, "score_change_display": "-2", "confidence_change": 1, "article_change": -2, "tone": "neutral", "height": 4, "articles": 3, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "22 Jun 23:59", "short_label": "22 Jun", "collected_at": "2026-06-22T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 4, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "24 Jun 23:59", "short_label": "24 Jun", "collected_at": "2026-06-24T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 1, "score_change_display": "+1", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "25 Jun 23:59", "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 2, "tone": "neutral", "height": 4, "articles": 7, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "26 Jun 23:59", "short_label": "26 Jun", "collected_at": "2026-06-26T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 8, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "27 Jun 23:59", "short_label": "27 Jun", "collected_at": "2026-06-27T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 1, "score_change_display": "+1", "confidence_change": 3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 9, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "28 Jun 23:59", "short_label": "28 Jun", "collected_at": "2026-06-28T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 9, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "03 Jul 23:59", "short_label": "03 Jul", "collected_at": "2026-07-03T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": -6, "article_change": 1, "tone": "neutral", "height": 4, "articles": 10, "confidence": 18, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "05 Jul 23:59", "short_label": "05 Jul", "collected_at": "2026-07-05T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 11, "confidence": 17, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "09 Jul 23:59", "short_label": "09 Jul", "collected_at": "2026-07-09T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 12, "confidence": 15, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "10 Jul 23:59", "short_label": "10 Jul", "collected_at": "2026-07-10T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 13, "confidence": 15, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "16 Jul 23:59", "short_label": "16 Jul", "collected_at": "2026-07-16T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 14, "confidence": 14, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "17 Jul 23:59", "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 4, "tone": "neutral", "height": 4, "articles": 18, "confidence": 14, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "18 Jul 23:59", "short_label": "18 Jul", "collected_at": "2026-07-18T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -1, "score_change_display": "-1", "confidence_change": 15, "article_change": 2, "tone": "neutral", "height": 4, "articles": 20, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "20 Jul 23:59", "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 21, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "21 Jul 23:59", "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 1, "score_change_display": "+1", "confidence_change": -1, "article_change": -1, "tone": "neutral", "height": 4, "articles": 20, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "22 Jul 23:59", "short_label": "22 Jul", "collected_at": "2026-07-22T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 20, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "25 Jul 23:59", "short_label": "25 Jul", "collected_at": "2026-07-25T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": -2, "tone": "neutral", "height": 4, "articles": 18, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "26 Jul 23:59", "short_label": "26 Jul", "collected_at": "2026-07-26T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -1, "score_change_display": "-1", "confidence_change": 4, "article_change": 0, "tone": "neutral", "height": 4, "articles": 18, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -1, "score_change_display": "-1", "confidence_change": 4, "article_change": 8, "tone": "neutral", "height": 4, "articles": 26, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "28 Jul 23:59", "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 26, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "29 Jul 23:59", "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 1, "score_change_display": "+1", "confidence_change": 3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 27, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 29, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "31 Jul 23:59", "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 30, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "01 Aug 23:59", "short_label": "01 Aug", "collected_at": "2026-08-01T23:59:59.999999+00:00", "score": 46, "delta": -4, "score_change": -4, "score_change_display": "-4", "confidence_change": 6, "article_change": 2, "tone": "neutral", "height": 8, "articles": 32, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "02 Aug 23:59", "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score": 46, "delta": -4, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 8, "articles": 32, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "03 Aug 23:59", "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 1, "score_change_display": "+1", "confidence_change": -1, "article_change": 2, "tone": "neutral", "height": 6, "articles": 34, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "06 Aug 23:59", "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 0, "score_change_display": "+0", "confidence_change": -6, "article_change": 2, "tone": "neutral", "height": 6, "articles": 36, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 38, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 6, "score_change_display": "+6", "confidence_change": 13, "article_change": 1, "tone": "neutral", "height": 8, "articles": 39, "confidence": 36, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -4, "score_change_display": "-4", "confidence_change": 7, "article_change": 4, "tone": "neutral", "height": 4, "articles": 43, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 2, "score_change_display": "+2", "confidence_change": 2, "article_change": 3, "tone": "neutral", "height": 4, "articles": 46, "confidence": 45, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 6, "articles": 47, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "14 Aug 23:59", "short_label": "14 Aug", "collected_at": "2026-08-14T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -2, "score_change_display": "-2", "confidence_change": -1, "article_change": 4, "tone": "neutral", "height": 4, "articles": 51, "confidence": 42, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "15 Aug 23:59", "short_label": "15 Aug", "collected_at": "2026-08-15T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 1, "score_change_display": "+1", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 51, "confidence": 41, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "16 Aug 23:59", "short_label": "16 Aug", "collected_at": "2026-08-16T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": -3, "tone": "neutral", "height": 4, "articles": 48, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "19 Aug 23:59", "short_label": "19 Aug", "collected_at": "2026-08-19T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -8, "article_change": -2, "tone": "neutral", "height": 4, "articles": 46, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "21 Aug 23:59", "short_label": "21 Aug", "collected_at": "2026-08-21T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": -1, "tone": "neutral", "height": 4, "articles": 45, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "22 Aug 23:59", "short_label": "22 Aug", "collected_at": "2026-08-22T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -3, "score_change_display": "-3", "confidence_change": 4, "article_change": 2, "tone": "neutral", "height": 4, "articles": 47, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "24 Aug 23:59", "short_label": "24 Aug", "collected_at": "2026-08-24T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 48, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "25 Aug 23:59", "short_label": "25 Aug", "collected_at": "2026-08-25T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 50, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "26 Aug 23:59", "short_label": "26 Aug", "collected_at": "2026-08-26T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -1, "score_change_display": "-1", "confidence_change": 5, "article_change": -4, "tone": "neutral", "height": 4, "articles": 46, "confidence": 37, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "27 Aug 23:59", "short_label": "27 Aug", "collected_at": "2026-08-27T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 3, "score_change_display": "+3", "confidence_change": 2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 47, "confidence": 39, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "28 Aug 23:59", "short_label": "28 Aug", "collected_at": "2026-08-28T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 4, "articles": 47, "confidence": 36, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "30 Aug 05:05", "short_label": "30 Aug", "collected_at": "2026-08-30T05:05:22.265128+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": -2, "tone": "neutral", "height": 4, "articles": 45, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v10", "live_version": "evidence-v10", "comparable_to_live": true, "reconstructed": true, "observations": 50, "span_label": "117 days", "first_score": 50, "latest_score": 52, "net_change": 2, "net_change_display": "+2", "direction": "Broadly stable", "high_score": 54, "low_score": 46, "latest_confidence": 34, "confidence_change": 34, "latest_articles": 45, "article_change": 44, "latest_label": "30 Aug 05:05", "latest_evidence_label": "Provisional", "chart_rows": [{"label": "04 May 23:59", "short_label": "04 May", "collected_at": "2026-05-04T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 1, "confidence": 0, "evidence_status": "insufficient", "evidence_label": "Insufficient", "score_version": "evidence-v10", "reconstructed": true, "x": 42.0, "y": 135.0}, {"label": "05 May 23:59", "short_label": "05 May", "collected_at": "2026-05-05T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 26, "article_change": 1, "tone": "neutral", "height": 4, "articles": 2, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 60.7, "y": 135.0}, {"label": "06 May 23:59", "short_label": "06 May", "collected_at": "2026-05-06T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 3, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 79.4, "y": 135.0}, {"label": "22 May 23:59", "short_label": "22 May", "collected_at": "2026-05-22T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -1, "score_change_display": "-1", "confidence_change": 3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 4, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 98.1, "y": 136.8}, {"label": "29 May 23:59", "short_label": "29 May", "collected_at": "2026-05-29T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 3, "score_change_display": "+3", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 116.8, "y": 131.4}, {"label": "21 Jun 23:59", "short_label": "21 Jun", "collected_at": "2026-06-21T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -2, "score_change_display": "-2", "confidence_change": 1, "article_change": -2, "tone": "neutral", "height": 4, "articles": 3, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 135.5, "y": 135.0}, {"label": "22 Jun 23:59", "short_label": "22 Jun", "collected_at": "2026-06-22T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 4, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 154.2, "y": 135.0}, {"label": "24 Jun 23:59", "short_label": "24 Jun", "collected_at": "2026-06-24T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 1, "score_change_display": "+1", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 172.9, "y": 133.2}, {"label": "25 Jun 23:59", "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 2, "tone": "neutral", "height": 4, "articles": 7, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 191.6, "y": 133.2}, {"label": "26 Jun 23:59", "short_label": "26 Jun", "collected_at": "2026-06-26T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 8, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 210.2, "y": 133.2}, {"label": "27 Jun 23:59", "short_label": "27 Jun", "collected_at": "2026-06-27T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 1, "score_change_display": "+1", "confidence_change": 3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 9, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 228.9, "y": 131.4}, {"label": "28 Jun 23:59", "short_label": "28 Jun", "collected_at": "2026-06-28T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 9, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 247.6, "y": 133.2}, {"label": "03 Jul 23:59", "short_label": "03 Jul", "collected_at": "2026-07-03T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": -6, "article_change": 1, "tone": "neutral", "height": 4, "articles": 10, "confidence": 18, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 266.3, "y": 135.0}, {"label": "05 Jul 23:59", "short_label": "05 Jul", "collected_at": "2026-07-05T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 11, "confidence": 17, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 285.0, "y": 135.0}, {"label": "09 Jul 23:59", "short_label": "09 Jul", "collected_at": "2026-07-09T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 12, "confidence": 15, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 303.7, "y": 135.0}, {"label": "10 Jul 23:59", "short_label": "10 Jul", "collected_at": "2026-07-10T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 13, "confidence": 15, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 322.4, "y": 135.0}, {"label": "16 Jul 23:59", "short_label": "16 Jul", "collected_at": "2026-07-16T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 14, "confidence": 14, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 341.1, "y": 135.0}, {"label": "17 Jul 23:59", "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 4, "tone": "neutral", "height": 4, "articles": 18, "confidence": 14, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 359.8, "y": 135.0}, {"label": "18 Jul 23:59", "short_label": "18 Jul", "collected_at": "2026-07-18T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -1, "score_change_display": "-1", "confidence_change": 15, "article_change": 2, "tone": "neutral", "height": 4, "articles": 20, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 378.5, "y": 136.8}, {"label": "20 Jul 23:59", "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 21, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 397.2, "y": 136.8}, {"label": "21 Jul 23:59", "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 1, "score_change_display": "+1", "confidence_change": -1, "article_change": -1, "tone": "neutral", "height": 4, "articles": 20, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 415.9, "y": 135.0}, {"label": "22 Jul 23:59", "short_label": "22 Jul", "collected_at": "2026-07-22T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 20, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 434.6, "y": 135.0}, {"label": "25 Jul 23:59", "short_label": "25 Jul", "collected_at": "2026-07-25T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": -2, "tone": "neutral", "height": 4, "articles": 18, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 453.3, "y": 135.0}, {"label": "26 Jul 23:59", "short_label": "26 Jul", "collected_at": "2026-07-26T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -1, "score_change_display": "-1", "confidence_change": 4, "article_change": 0, "tone": "neutral", "height": 4, "articles": 18, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 472.0, "y": 136.8}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -1, "score_change_display": "-1", "confidence_change": 4, "article_change": 8, "tone": "neutral", "height": 4, "articles": 26, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 490.7, "y": 138.6}, {"label": "28 Jul 23:59", "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 26, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 509.3, "y": 136.8}, {"label": "29 Jul 23:59", "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 1, "score_change_display": "+1", "confidence_change": 3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 27, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 528.0, "y": 135.0}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 29, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 546.7, "y": 135.0}, {"label": "31 Jul 23:59", "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 30, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 565.4, "y": 135.0}, {"label": "01 Aug 23:59", "short_label": "01 Aug", "collected_at": "2026-08-01T23:59:59.999999+00:00", "score": 46, "delta": -4, "score_change": -4, "score_change_display": "-4", "confidence_change": 6, "article_change": 2, "tone": "neutral", "height": 8, "articles": 32, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 584.1, "y": 142.3}, {"label": "02 Aug 23:59", "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score": 46, "delta": -4, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 8, "articles": 32, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 602.8, "y": 142.3}, {"label": "03 Aug 23:59", "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 1, "score_change_display": "+1", "confidence_change": -1, "article_change": 2, "tone": "neutral", "height": 6, "articles": 34, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 621.5, "y": 140.5}, {"label": "06 Aug 23:59", "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 0, "score_change_display": "+0", "confidence_change": -6, "article_change": 2, "tone": "neutral", "height": 6, "articles": 36, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 640.2, "y": 140.5}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 38, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 658.9, "y": 138.6}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 6, "score_change_display": "+6", "confidence_change": 13, "article_change": 1, "tone": "neutral", "height": 8, "articles": 39, "confidence": 36, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 677.6, "y": 127.7}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -4, "score_change_display": "-4", "confidence_change": 7, "article_change": 4, "tone": "neutral", "height": 4, "articles": 43, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 696.3, "y": 135.0}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 2, "score_change_display": "+2", "confidence_change": 2, "article_change": 3, "tone": "neutral", "height": 4, "articles": 46, "confidence": 45, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 715.0, "y": 131.4}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": 1, "score_change_display": "+1", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 6, "articles": 47, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 733.7, "y": 129.5}, {"label": "14 Aug 23:59", "short_label": "14 Aug", "collected_at": "2026-08-14T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -2, "score_change_display": "-2", "confidence_change": -1, "article_change": 4, "tone": "neutral", "height": 4, "articles": 51, "confidence": 42, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 752.4, "y": 133.2}, {"label": "15 Aug 23:59", "short_label": "15 Aug", "collected_at": "2026-08-15T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 1, "score_change_display": "+1", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 51, "confidence": 41, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 771.1, "y": 131.4}, {"label": "16 Aug 23:59", "short_label": "16 Aug", "collected_at": "2026-08-16T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": -3, "tone": "neutral", "height": 4, "articles": 48, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 789.8, "y": 131.4}, {"label": "19 Aug 23:59", "short_label": "19 Aug", "collected_at": "2026-08-19T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -8, "article_change": -2, "tone": "neutral", "height": 4, "articles": 46, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 808.4, "y": 131.4}, {"label": "21 Aug 23:59", "short_label": "21 Aug", "collected_at": "2026-08-21T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": -1, "tone": "neutral", "height": 4, "articles": 45, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 827.1, "y": 131.4}, {"label": "22 Aug 23:59", "short_label": "22 Aug", "collected_at": "2026-08-22T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -3, "score_change_display": "-3", "confidence_change": 4, "article_change": 2, "tone": "neutral", "height": 4, "articles": 47, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 845.8, "y": 136.8}, {"label": "24 Aug 23:59", "short_label": "24 Aug", "collected_at": "2026-08-24T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 48, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 864.5, "y": 135.0}, {"label": "25 Aug 23:59", "short_label": "25 Aug", "collected_at": "2026-08-25T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 50, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 883.2, "y": 135.0}, {"label": "26 Aug 23:59", "short_label": "26 Aug", "collected_at": "2026-08-26T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -1, "score_change_display": "-1", "confidence_change": 5, "article_change": -4, "tone": "neutral", "height": 4, "articles": 46, "confidence": 37, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 901.9, "y": 136.8}, {"label": "27 Aug 23:59", "short_label": "27 Aug", "collected_at": "2026-08-27T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 3, "score_change_display": "+3", "confidence_change": 2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 47, "confidence": 39, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 920.6, "y": 131.4}, {"label": "28 Aug 23:59", "short_label": "28 Aug", "collected_at": "2026-08-28T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 4, "articles": 47, "confidence": 36, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 939.3, "y": 131.4}, {"label": "30 Aug 05:05", "short_label": "30 Aug", "collected_at": "2026-08-30T05:05:22.265128+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": -2, "tone": "neutral", "height": 4, "articles": 45, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 958.0, "y": 131.4}], "chart_points": "42.0,135.0 60.7,135.0 79.4,135.0 98.1,136.8 116.8,131.4 135.5,135.0 154.2,135.0 172.9,133.2 191.6,133.2 210.2,133.2 228.9,131.4 247.6,133.2 266.3,135.0 285.0,135.0 303.7,135.0 322.4,135.0 341.1,135.0 359.8,135.0 378.5,136.8 397.2,136.8 415.9,135.0 434.6,135.0 453.3,135.0 472.0,136.8 490.7,138.6 509.3,136.8 528.0,135.0 546.7,135.0 565.4,135.0 584.1,142.3 602.8,142.3 621.5,140.5 640.2,140.5 658.9,138.6 677.6,127.7 696.3,135.0 715.0,131.4 733.7,129.5 752.4,133.2 771.1,131.4 789.8,131.4 808.4,131.4 827.1,131.4 845.8,136.8 864.5,135.0 883.2,135.0 901.9,136.8 920.6,131.4 939.3,131.4 958.0,131.4", "changes": [{"label": "30 Aug 05:05", "short_label": "30 Aug", "collected_at": "2026-08-30T05:05:22.265128+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": -2, "tone": "neutral", "height": 4, "articles": 45, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "28 Aug 23:59", "short_label": "28 Aug", "collected_at": "2026-08-28T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 4, "articles": 47, "confidence": 36, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "27 Aug 23:59", "short_label": "27 Aug", "collected_at": "2026-08-27T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 3, "score_change_display": "+3", "confidence_change": 2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 47, "confidence": 39, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "26 Aug 23:59", "short_label": "26 Aug", "collected_at": "2026-08-26T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -1, "score_change_display": "-1", "confidence_change": 5, "article_change": -4, "tone": "neutral", "height": 4, "articles": 46, "confidence": 37, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "25 Aug 23:59", "short_label": "25 Aug", "collected_at": "2026-08-25T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 50, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "24 Aug 23:59", "short_label": "24 Aug", "collected_at": "2026-08-24T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 48, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "22 Aug 23:59", "short_label": "22 Aug", "collected_at": "2026-08-22T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -3, "score_change_display": "-3", "confidence_change": 4, "article_change": 2, "tone": "neutral", "height": 4, "articles": 47, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "21 Aug 23:59", "short_label": "21 Aug", "collected_at": "2026-08-21T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": -1, "tone": "neutral", "height": 4, "articles": 45, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}